Clinical and molecular markers in endometrial cancer. Studying prognostic and predictive biomarkers that can help to individualise therapeutic decisions by Werner, Henrica Maria Johanna
 Dissertation for the degree philosophiae doctor (PhD)  
at the University of Bergen 
 
 
Dissertation date: May 20th  2014 
&OLQLFDODQGPROHFXODUPDUNHUVLQ
HQGRPHWULDOFDQFHU
6WXG\LQJSURJQRVWLFDQGSUHGLFWLYHELRPDUNHUVWKDWFDQKHOSWR
LQGLYLGXDOLVHWKHUDSHXWLFGHFLVLRQV
+HQULFD0DULD-RKDQQD:HUQHU


ͳ

Clinical and molecular markers in endometrial cancer 
 
Studying prognostic and predictive biomarkers that can help to individualise 
therapeutic decisions 
 
 
 
 
 
Centre for Cancer Biomarkers, Department of Clinical Science, University of  
Bergen, Bergen, Norway 
 
 
 
 
 
 
 
 
 
 
Henrica Maria Johanna Werner, MD, MRCOG 
Dissertation for the degree of philosophiae doctor (PhD) at  
the University of Bergen 
May 20th, 2014  
ʹ

As I Grew Older 
It was a long time ago. 
I have almost forgotten my dream. 
But it was there then, 
In front of me, 
Bright like a sun 
My dream. 
And then the wall rose, 
Rose slowly, 
Slowly, 
Between me and my dream. 
Rose until it touched the sky 
The wall. 
Shadow. 
I am black. 
I lie down in the shadow. 
No longer the light of my dream before me, 
Above me. 
Only the thick wall. 
Only the shadow. 
My hands! 
My dark hands! 
Break through the wall! 
Find my dream! 
Help me to shatter this darkness, 
To smash this night, 
To break this shadow 
Into a thousand lights of sun, 
Into a thousand whirling dreams 
Of sun! 
 
James Langston Hughes, 1902-1967 
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Synopsis  
Background: Endometrial carcinoma is one of the most common cancer types in women, 
and incidence is increasing globally. Although many cancers are detected at an early stage 
and will be treated adequately with surgery alone, 15-20% of cancers will recur. After 
systemic recurrence, median survival approximates 7-12 months, in spite of treatment, 
with no improvement over the last decades. Our abilities to predict which patients will 
suffer recurrence, give ample room for improvement and robust prognostic biomarkers 
are needed to better recognise these high-risk patients. Response rates to medical 
treatment, both conventional and targeted, do not pass 40%, and are often considerably 
lower, even more so in the recurrent setting. Contrasting some other frequent cancer types 
such as breast and colorectal, in endometrial cancer algorithms, predictive biomarkers to 
support treatment choices are non-existent. Using preclinical models and large 
prospectively collected population-based patient series, potential biomarkers can be 
studied and tested at a pre-trial stage, which can accelerate the process of their 
identification and development, and increase the chance of succesfull trials. 
 
Objectives: We studied clinical and molecular variables for their abilities to function as 
prognostic or predictive biomarkers, with the ultimate aim to improve and individualise 
treatment strategies for endometrial cancer patients. 
Exploring the behaviour of these biomarkers during cancer progression, followed as a 
logical consequence. 
 
Materials and Methods: For all studies included in this thesis (studies 1-5) clinical data, 
including follow-up data, have been retrieved and analysed, either from the Haukeland 
University Hospital Series or from the significantly larger MoMaTEC series. The 
hyperplasia cohort has been studied in paper 4 and (paired) primary tumours and 
metastases in studies 4+5.  From the biobank material, FFPE tissue has been used for 
immunohistochemistry (ARID1A; study 4, stathmin1; study 5), snap-frozen tissue for 
RNA microarrays (study 4) and haematoxylin stained frozen sections (study 3). For 
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studies 1 and 2 only clinical data was used. Cell-line studies, including dose response 
studies, viral transfection techniques and immunoblotting formed a strong basis under 
study 5. 
 
Results: After restaging all 1268 included patients, we demonstrated an improvement and 
simplification of the prognostic stratification using the FIGO 2009 version. In stage 1 
patients, the myometrial infiltration depth was an independent prognostic factor, only for 
those patients that did not undergo lymphadenectomy. Cox multivariate survival analysis 
showed FIGO 2009 to be a stronger, independent prognostic factor than FIGO 1988. 
(study 1) 
The 16% (207) tumours with discordant risk between preoperative and operative 
specimens, proved to be an interesting group with intermediate prognosis and risk of 
lymph node metastasis, in the entire dataset (n=1374) and in stage 1 tumours only 
(n=954). Cox multivariate survival analysis showed the risk classification to have 
independent prognostic value, and different hazard rates for the concordant high risk (HR 
5.1) and discordant groups (HR 2.7 and 2.9). (study 2) 
High tumour cell content (n=136, 50%) was in our series associated with more aggressive 
disease and reduced disease specific survival. (study 3) 
Loss of ARID1A was linked to the endometrioid and clear cell subtypes, and associated 
with less aggressive disease, with the exception of the positive association with deep 
myometrial infiltration. No relation was found between loss of ARID1A and survival. 
Loss was noticed in a considerable percentage of the hyperplasias with atypia; this 
percentage further increased with disease progression. (study 4) 
Stathmin1 knockdown in cell lines was associated with increased apoptosis after 
paclitaxel treatment. Patients with high stathmin1 level showed worse response to 
paclitaxel containing chemotherapy, but not to other treatments, compared to patients 
with normal stathmin level using RECIST criteria. In Cox multivariate analysis, 
stathmin1 was an independent predictor of survival only in the subgroup of patients who 
received paclitaxel containing chemotherapy. (study 5) 
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Conclusions: The FIGO 2009 classification system both simplified and improved 
prognostic stratification abilities compared to the previous system from 1988. (study 1) 
Through integration of the preoperative histology with the final or operative histology, 
prognostic information can be further improved, especially when discordance between 
both results exists and results in the identification of subgroups with intermediate risk for 
metastatic spread and disease specific death that currently go unnoticed. (study 2) 
The 80% tumour-cell content cutoff, meant to ensure high tumour purity, is, in 
endometrial cancer, associated with high-risk clinicopathological characteristics and 
reduced disease specific survival and may thus introduce an unintended selection bias. 
(study 3)  
Loss of ARID1A occurs most in endometrioid and clear cell subtypes and is 
predominantly linked to clinicopathological parameters of less aggressive disease, but 
lacks correlation with survival. Loss starts early in endometrioid endometrial cancer 
carcinogenesis and further increases with tumour progression. (study 4) 
Stathmin1 has potential as a predictive biomarker for response to paclitaxel containing 
chemotherapeutic regimes in endometrial cancer. (study 5) 
Biomarker switch is a frequent phenomenon during endometrial cancrinoma disease 
progression and re-assessment of biomarker status in metastatic disease may be relevant. 
(study 4 and 5) 
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1. INTRODUCTION 
Malignancies of the corpus uteri can be broadly classified into epithelial malignancies 
(endometrial carcinomas and precursor lesions), mesenchymal malignancies (uterine 
sarcomas), mixed epithelial and mesenchymal malignancies of the uterus (malignant 
mixed müllerian tumours) and trophoblastic malignancies. 
Endometrial carcinoma originates in the endometrium. It is the fourth most common 
cancer in women in the western world and currently1the 6th (USA) or 8th (Europe) cause 
of cancer-related death in women. 
 
1.1.  Epidemiology 
1.1a. Incidence 
Incidence rates vary widely across geographical regions worldwide. Recent publications 
from the USA, report an age-adjusted endometrial cancer incidence of 24.3/100.000, the 
highest world-wide2. In Western Europe the age-adjusted incidences are somewhat lower; 
Norway; 16.53, UK; 19.54, and the Netherlands; 165. Contrasting this, in the less affluent 
regions of the world, such as larger parts of Africa and South Central Asia, the incidence 
is as low as 2.1/100.0006 (Figure 1a). The cumulative risk of endometrial cancer by the 
age of 75 has been calculated between 1.6 and 2.7% in the western world2,7,8. 
Although endometrial cancers in teenagers has been described9, endometrial cancer is 
usually not considered a significant risk below the age of 35. However, in women 
presenting with anovulatory cycles, up to 14% of will be diagnosed with hyperplasia with 
atypia or endometrial cancer2,10. In general, endometrial cancer remains a disease of the 
elderly woman, with the highest incidences shown in the 6th and 7th decade of life2,3,11. 
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Figure 1. Age-standardised endometrial cancer incidence12 
1a. World age-standardised incidence per 100.000 population (female), 2008 estimates 
1b. UK age-standardised incidence per 100.000 population (female), trends over time 1975-2010 
Figures adapted; reproduced with permission 
 
1.1b. Mortality 
Overall, the prognosis of endometrial cancer is good, with a mortality rate reported 
between 2.4/100.0008 and  4.3/100.0002. The 2011 data from the Norwegian cancer 
registry showed a 5-year survival of 84.4% for all endometrial cancer patients combined3. 
As many women are diagnosed at an early stage, most women with endometrial cancer 
will not die from their cancer, the leading cause of death (36%) in the entire population is 
indeed cardiovascular disease13. However, in women dying within 5 years of their 
diagnosis, most women die of disease13. Underscoring this, after systemic recurrence of 
the disease, median survival does not pass beyond 7-12 months, in spite of the currently 
available treatment options13-16. 
Survival (and thus mortality) can be described in multiple ways, such as overall or disease 
specific. Considering that endometrial carcinoma is predominantly a disease of the elderly 
woman, with many intercurrent diseases and possibly deaths, and considering that many 
tumours do not run an aggressive course; it is highly relevant to use disease specific 
survival. Long term follow-up after treatment, also including deaths potentially related to 
side effects from treatments (e.g. external radiotherapy), has recently proven relevant17.  
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There is a rise in the endometrial cancer incidence globally, across all age cohorts except 
premenopausal women2,3,7, which for a larger degree has been ascribed to the obesity 
epidemic18-21 and the increasing life expectancy (Figure 1b, 2). The lay public and thus 
the potential future patients, are however for the bigger part not aware of this increased 
life style risk22. A study by Renehan et al.23 showed that in Europe alone, up to 30% of 
the endometrial cancers may be attributable to obesity, a significantly stronger association 
than in most other cancer types.  A relative risk increase of 2.89 (2.26-3.18) for every 10 
units BMI increase) was reported by the Million Women Study24. Whether and how 
obesity relates to disease specific survival is less clear and an active area of research. In 
large population based studies, women with high BMI tend to have better survival, 
although not with independent prognostic value25,26, and may be related to the stronger 
association with less aggressive histology18,25. 
 
Figure 2. Increasing obesity rates among adults in European countries, 1990, 2000 and 2010 (or 
nearest years)27
	Ǣ 
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There are many confounding factors though, including obesity related comorbidity and 
life expectancy and the increased risk of complications through surgical and/or adjuvant 
treatment. 
 
1.2. Etiology  
1.2a. Risk factors 
Most endometrial carcinomas are sporadic. The majority (roughly 80%) arises on a 
background of atypical hyperplasia after long-term exposure to unopposed oestrogens and 
are histologically endometrioid endometrial carcinoomas28. Classical risk factors include 
obesity, chronically anovulatory cycles and diabetes, but also prolonged tamoxifen use 
and unopposed menopausal hormone treatment; all stimulating growth of the 
endometrium. In addition to (unopposed) oestrogen production, obesity is associated with 
insulin resistance, ovarian androgen excess, anovulation and low progesterone levels, 
leading to changes in adipocyte and inflammatory factor levels21,28. As a consequence, 
proliferation and angiogenesis are stimulated in the endometrium and apoptosis is 
inhibited28. Tamoxifen is a selective estrogen receptor modulator that, while having 
antagonistic effects in some tissues, like the breast, has agonistic effects in others, 
including the uterus (estimated relative risk of endometrial cancer =2)29,30.  
Additionally, increased risk is associated with nulliparity, positive family history of 
endometrial cancer31 and diabetes20,28.  
The remaining 15-20% of endometrial cancers arise on an atrophic endometrium, and are 
likely preceded by endometrial intraepithelial carcinoma. These are often grouped 
together as non-endometrioid tumours. In contrast to long term believe, they as well have 
been associated with obesity in recent publications, although to a lesser extent than the 
endometrioid variant18,21,32,33. A pooled analysis recently concluded even that other 
riskincreasing or reducing factors such as diabetes on the one hand and parity and oral 
contraception on the other, and were equally associated with serous as with endometrioid 
subtypes33. A positive history of breast cancer though, specifically increases risk of the 
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non-endometrioid tumours34,35. A small percentage of endometrial carcinomas are related 
to hereditary factors. HNPPC (Lynch syndrome, affecting 0.1-0.2% of the general 
population), due to a germ line mutation in one of the DNA mismatch repair genes, puts 
its carriers at increased risk of endometrial cancer (44%)36,37 alongside their risk of 
colorectal cancer and several other cancer types. 
 
Some of the most important negative risk factors or risk reducing factors are life style 
modifiable, underscoring the need for increased public awareness of endometrial cancer 
risk factors. These include maintenance of a normal BMI, physical activity and oral 
contraceptive use (potentially including the Mirena® coil38,39). Grand multiparity has 
been associated with reduced risk, most likely though the high progesterone production 
during pregnancies. With regards to smoking, literature is conflicting with reports 
suggesting reduced20,40 as well as increased risk41. 
 
1.2b. ‘Type 1’ and ‘Type 2’ endometrial cancer 
Based on epidemiology and clinical behaviour, but also on light microscopy appearance, 
Bokhman coined the term ‘type 1’ and ‘type 2’ cancers42, considering low grade (grade 1 
and 2) endometrioid tumours as type 1 and high-grade (grade 3) non-endometrioid 
tumours as type 2 tumours (Table 1). However, the assignment of the high-grade 
endometrioid tumours remains controversial, often being grouped with the type 2 tumours, 
although in the original publication42, being endometrioid tumours, they were considered 
type I.  
 
1.2c. Tumour biology 
From a (tumour) biology point of view, cells function as busy crossroads, constantly 
receiving large number of signals, including signals for growth and proliferation and 
apoptosis, and integrating these into responses, whilst they dynamically interact with 
other cells and tissues. Endometrial cells are no different. Robust homeostatic 
mechanisms further fine-tune these responses and correct for damage caused by external 
ʹ͵

factors and by f.e. spontaneous mutations that occurred in the cell. When a cell is 
damaged, repair mechanisms will try to correct this damage, and if impossible impose a 
self-destruction pathway of apoptosis43. Do such mechanisms fail and the error has 
occurred in a ‘cancer gene’, a cell may arise that is less responsive to external signals, and 
after multiple episodes of non-corrected damage in the same cell, a cancer may arise. 
Cancer genes are essentially normal genes that confer a growth advantage to the cell, such 
as growth signal autonomy or invasion potential, when dysregulated. Hanahan and 
Weinberg defined ‘hallmarks of cancer’, characteristics that give the cell a growth 
advantage, indispensable for carcinogenesis44,45. Three main types of cancer genes should 
be highlighted. Oncogenes or tumour inducing genes, arise from normal genes (proto-
oncogenes) that regulate cell growth and differentiation through f.e. mutation or 
overexpression. Examples include MYC, RAS and different RTK’s.  Tumour suppressor 
genes repress cell replication and loss of their proteins through mutation, promotor 
hypermethylation or other mechanisms may therefore accelerate growth. Classic tumour 
suppressor genes are TP53 and the retinoblastoma protein. We have investigated a 
recently discovered ovarian tumour suppressor gene, ARID1A, for its tumour-biological 
and prognostic value in endometrial carcinoma (this thesis). DNA damage response genes 
induce apoptosis when cells are damaged beyond repair. Dysfunctional genes may allow 
damaged cells to survive and proliferate and possibly gain growth benefit; BRCA and FAS 
mutations operate in this way. 
Different cancer types often show a characteristic pattern of aberrations in tumour 
suppressors and oncogenes or pathways involved.  
Endometrioid and non-endometrioid tumours have a largely different set of aberrations, 
and, in a way, can be considered 2 different diseases16,46,47, molecularly supporting the 
type 1 and 2 classification. 
Type 1 cancers are characterised by a high mutational frequency and microsatellite 
instability. The most important aberrant pathway in type 1 endometrial carcinomas is the 
PI3K pathway, with sometimes multiple aberrations in this pathway (such as 
ʹͶ

simultaneous loss of PTEN and PIK3CA mutations) in one tumour. In addition the RAS-
RAF-MAPK pathway is frequently dysregulated. 
In contrast the type 2 cancers are characterised by chromosomal instability and TP53 
mutation. Also here, the PI3K pathway is frequently dysregulated, however, now 
charecterised by amplifications in PIK3CA or overexpression/amplification of the 
receptor thyrosine kinases (HER2, FGFR2, EGFR), much more than loss of PTEN and 
PIK3CA mutations. Of note is that whereas in type 1 cancers PIK3CA mutations are either 
in exon 9 (often the low grade tumours) or exon 20, in type 2 mutations appear 
exclusively in exon 20, highlighting clearly a different molecular basis between the two 
subtypes16,46-48. A number of key molecular aberrations type 1 and type 2 are associated 
with, are indicated in Table 1. However, as can be observed, no molecular marker or 
combination of markers is absolute for either type, and classical type 2 characteristics can 
be found in type 1 cancers and v.v.. As such, the division in type 1 and type 2 is not 
perfect. Challenges include the ‘mixed’ tumours that have both endometrioid and 
serous/clear cell components and which are therefore difficult to fit into this classification. 
Further, tumours as heterogenous as serous, clear cell and carcinosarcomas are all 
classified as type 2, but are molecularly and behaviourally very different49,50. 
In recent publications it has been argued50 that the type 1/type 2 division does not reflect 
biology optimally and that a three-tiered system may more appropriately assign individual 
tumours to categories and leave less ‘(morphologically) ambiguous’ and likely 
heterogenous tumours inappropriately and inconsistently assigned51-54. This additional, 
molecularly intermediate type may in addition be intermediate in prognosis.          
 
An optimal (cancer) classification is characterised by high reproducibility and biological 
relevance, containing prognostic and ideally predictive information51. Currently existing 
classifications are suboptimal for endometrial carcinoma. For, although in general the 
type I tumours fare better than the type II tumours, still approximately 15% of the type I 
tumours recur and 50% of the type II do not16,42,46, underscoring that our current 
distinction has to be further improved. 
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1.2d. Other approaches 
Rather than only trying to categorise within a cancer type, tumour types can also 
be compared to other tumour types for similarities and associations between 
subtypes based on their molecular features. As an example, TCGA56 has started to 
perform, besides integrative analyses on large numbers of tumour samples from 
one tumour type (such as endometrium, ovary or kidney), cross-tumour type 
analyses, noting striking molecular similarities between serous endometrial, basal 
breast and high-grade serous ovarian cancer57 (Fig 3). Also, similarities were noted 
between endometrioid endometrial and colorectal cancer57. Such molecular 
resemblance can enhance our understanding of individual diseases and suggest 
treatment opportunities. 
 
Figure 3. Similarities across different cancers57 
a. Cover of the New York Times, New England edition, May 2nd 2013, showing lay press 
attention to an endometrial cancer study57, which included a comparison between 
underlying genetic aberrations in serous ovarian, basal breast and serous endometrial 
cancer. 
b. Figure showing the somatic copy number alterations for each tumour type 
c. Figure showing the frequency of genomic aberrations, present in at least 10% of one 
tumour type 
ʹ͹

b and c, adapted; reproduced with permission 
 
1.3. Clinic 
1.3a. Clinical presentation 
(Abnormal) vaginal bleeding is an early symptom in up to 90% of patients58 and 
most endometrial carcinomas are therefore diagnosed at an early stage. Older 
women however are in comparison more often diagnosed with cancers at a higher 
stage and grade19 (and references therein). The first step in the diagnostic work-up 
in women with postmenopausal bleeding (cancer risk 1%) is (vaginal) ultrasound 
scanning assessing the endometrial lining, followed by biopsy taking for 
histological confirmation, using either office methods or curettage if it appears 
thickened (>4mm58) or difficult to visualise. In the latter case, a 15% risk of cancer 
has been reported59. In pre- or perimenopausal women, the thickness of the 
endometrial lining is less informative due to cyclical hormonal fluctuations. As 
such, a suspect anamnesis combined with the presence of risk factors is sufficient 
to warrant a biopsy in these women.   
 
1.3b. Diagnostical process  
The histopathological results, confirming or refuting the diagnosis, allow for a first 
categorisation into low and high risk disease, looking at subtype and grade. One of 
the major challenges is to tailor the surgical treatment and limit procedures such as 
lymphadenectomy or radical hysterectomy to those patients who will benefit from 
them and not expose patients to potential complications unnecessarily. Both 
imaging and molecular features of the preoperative specimens are scrutinised for 
their abilities to better subdivide tumours as low or high risk. 
 
1.3c. Imaging 
Preoperative imaging assists in the acquisition of an as optimal as possible 
understanding of the disease extent, required to plan the surgical therapy and 
ʹͺ

includes imaging of the thorax (focusing on lung metastases) and pelvis/abdomen 
(estimating myometrial invasion depth and cervical stromal invasion and/or lymph 
node metastasis). Whilst X-ray is routinely used for the thorax, the optimal pelvic 
imaging technique is more controversial and may include (vaginal or abdominal) 
ultrasound, hysteroscopy, CT or/and MRI and is an area of active research (see 
biomarker section). 
 
1.4. Histopathological diagnosis 
1.4a. Histological subtypes 
The assignment of endometrial carcinomas to the various histological subtypes60 is 
of paramount importance as it impacts both the extent of surgery and need for 
adjuvant therapy, related to their risk of metastasis and recurrence.  
 
Endometrioid adenocarcinoma 
Glandular structures are a prominent feature in this subtype, resembling the 
original endometrium in varying degrees of differentiation, but it can in addition 
contain solid areas or areas with more papillary growth. The tumour often arises 
on a background of endometrial hyperplasia. Endometrioid carcinomas are graded 
according to their nuclear grade and the glandular and solid (varying percentages) 
architecture (see 1.4b and Fig. 4). 
Serous adenocarcinoma 
The most frequent observation in this subtype is a (micro) papillary architecture 
and individual cells that have detached from the tumour. No obvious precursor 
lesion is usually present, but the cancer likely progresses from endometrial 
intraepithelial carcinoma in an atrophic endometrium. The nuclear features are 
often pleomorphic and per definition high-grade (see Fig. 4). 
Clear cell adenocarcinoma 
ʹͻ

This subtype is characterised by hobnail, glycogen filled, cells, with often very 
atypical pleomorphic nuclei. Their architecture is usually papillary and/or solid 
with uniform, high-grade nuclear features (see Fig. 4). 
Mixed adenocarcinoma 
Mixed adenocarcinomas show components of endometrioid and clear cell/serous 
subtypes, with at least 10% of either type. They contain characteristics of both 
subtypes, but are thought to have progressed from an endometrioid tumour based 
on their molecular profile47. 
Carcinosarcoma  
Carcinosarcomas are a major subtype of the malignant mullerian mixed tumours 
that are histologically characterised by a combination of malignant epithelial 
(carcinomatous, often serous) and mesenchymal (sarcomatous) components with 
diffusely high-grade nuclear features. The origin of this tumour has been a matter 
of debate. However, the currently most accepted theory is that the sarcomatous 
components evolve through metaplastic dedifferentiation of carcinomatous 
tissue61,62 and that the tumour thus originally started as a carcinoma, which is 
supported by the molecular features of this subtype61-63. In line with this, since 
2009, the carcinosarcomas are included as an endometrial carcinoma subtype in 
the FIGO staging (see Fig. 4). 
 
͵Ͳ

 
Figure 4. Images of some of the most important endometrial carcinoma subtypes 
All images taken with normal light microscope using a 40x lens. A. Grade 1 
endometrioid; B. Grade 3 endometrioid; C. Clear cell; D. Serous; E. Carcinosarcoma   
Table 2 gives a quick overview of various of the prime characteristics of these 
subtypes. Further, a few subtypes with low frequency can be distinguished 
additionally, such as mucinous adenocarcinoma, small cell carcinoma and 
transitional cell carcinoma60. 
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1.4b. Grading 
Grading of tumours of the endometrioid subtype is based on the percentage of 
solid (non-squamous) growth and is three-tiered (grade 1: <5%, grade 2: 5-<50% 
and grade 3: 50%) and measures the degree of anaplasia (lack of differentiation) 
in the tumour cells, i.e. how much the tumour cells still resemble normal 
(endometrial) cells. When considerable nuclear atypia is present, such as 
pleomorphic or very prominent nucleoli, the grade is increased by ‘1’60. 
Approximately 40% of endometrioid tumours will be grade 1, 30% grade 2 and 
another 30% grade 3. The non-endometrioid subtypes are all considered to be 
poorly differentiated (grade 3) by virtue of their histology. As the cutoffs have 
been arbitrarily defined (not data-driven) and are prone to inter-observer variation, 
especially near the cutoff points, applying grading can be challenging64. Similarly, 
the nuclear atypia is not rigourously defined and therefore open to different 
interpretations, resulting in different grading of similar cases64. Various two-tiered 
systems have been suggested to be easier to use and more reproducible65,66. In this 
thesis, we have used the FIGO grading system categorised into two groups, i.e. 
grade 1 and 2 combined as low grade and grade 3 as high-grade, as often done in 
literature. Reproducibility, expressed as ț-value, has been reported to be fair to 
good for the three-tiered FIGO (0.41-0.65; interobserver and 0.66-0.73 
intraobserver) and somewhat higher for the two-tiered FIGO system (0.58-0.71; 
interobserver and 0.9 intraobserver)64. The binarised system also has independent 
prognostic value for disease specific survival and metastases64-66. 
 
1.4c. Staging 
Staging in cancer can either be clinical (based on physical examination, imaging 
results etc) or surgical-pathological (based on surgical findings and pathological 
examination of any removed tumour) and is cancer type dependent. In endometrial 
carcinoma staging has been surgical-pathological since 198867. Two alternative 
surgical-pathological classification systems exist. The majority of solid tumour 
͵͵

types are staged by the TNM classification, which is maintained by the American 
AJCC and the UICC68. Simply put, the T (tumour) stands for the size of the 
original tumour and spread to nearby tissues, the N (node) describes number, size 
and localisation of lymph node metastasis and M (metastasis) informs about 
distant metastases. 
However, in cancers of the female genital tract, such as endometrial carcinoma, 
the FIGO staging system is routinely applied, including in the articles used in this 
thesis69. The 2 systems fortunately show close resemblance as shown in Table 3. 
In the remainder of the thesis, only the FIGO system will be referred to. 
Using FIGO staging, the extent of tumour growth is divided into 4 stages; stage 1: 
confined to the uterus (72% of tumours is stage 1)70; stage 2: cervical (stromal) 
involvement (12%); stage 3: spread to the vagina, ovaries, parametria or lymph 
nodes (13%); and stage 4: presence of distant metastasis/growth into adjacent 
organs (3%). In 2009, a new version of the FIGO staging system for endometrial 
cancer was introduced, replacing the 1988 classification and incorporating 
progressive insights on f.e. the importance of myometrial invasion and positive 
para-aortic nodes after analysing large patient series69,71 (Table 3). The 2009 
version has been shown to be more prognostically informative than the 1988 
classification72,73 (this thesis).  
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That pathology results are not always optimally reproducible74,75, is reflected in 
the discordance rates in grade (up to 8%)75, in cervical stromal infiltration 
(concordance 0.35 to 0.69 (average 0.49))76 and histological subtype  
(reproducibility 0.62-0.86)75,77 after central pathology review, sometimes with 
clinical implications, and the discordance between expert gynaecological 
pathologists76. Comparing preoperative biopsies, obtained by office biopsy or 
curettage, with the corresponding hysterectomy specimen results, focusing on the 
ability to accurately predict the final histology, discordance rates ranging from 15-
32%78,79 have been reported. This may be related in part to tumour heterogeneity, 
not captured in the small volume of preoperative specimens, and the suboptimal 
reproducibility of endometrial cancer pathology reports compared to other 
gynaecological cancers. However, this discordance between curettings and tumour 
pathology results can also be exploited and explored for prognostic information 
(this thesis).  
 
1.5. Biomarkers 
A biomarker has been defined as a “characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenical processes, 
or pharmacological responses to a therapeutic intervention” by the Biomarkers 
Definitions Working Group80. Biomarkers can be as diverse as histopathological 
features, blood components, imaging, molecular markers, or in fact anything 
assessable or quantifiable in a patient. Both individual markers and so-called 
signatures or panels of markers in combination can be relevant. Various 
subdivisions in types of biomarkers can be made, of which one is highlighted here; 
a division in prognostic biomarkers, related to the survival of the patient 
independent of treatment and often implicated in the oncogenic processes, and 
predictive biomarkers, related to the expected response of a patient to a treatment. 
The latter are specifically interesting in the era of personalised medicine, to help 
tailor treatment to the patient’s needs. Importantly, for a biomarker to be of 
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clinical interest, it should provide incremental information beyond that already 
obtained from clinicopathological variables or other known predictors81. They 
should therefore be tested in addition to these, rather than independently.  
 
Unfortunately, the effect estimates in ‘highly cited studies’ of a high percentage 
(86%) of biomarkers appear (much) inflated when tested with independent 
datasets or meta-analyses, as recently demonstrated for 35 top-cited biomarkers, 
indicating that often publications on biomarkers are too optimistic or reach 
exaggerated associations81. It is therefore recommended that biomarkers should be 
validated in independent datasets or for example on different platforms. Further, 
the Enhancing the QUAlity and Transparency Of Health Research network 
(Equator)82 is an umbrella organisation focused on research paper quality 
improvement, through guideline development on accurate and complete reporting 
of key aspects, increasing generalisability of study results in different health 
research areas, such as PRISMA and CONSORT. The reporting recommendations 
for tumour marker prognostic studies are abbreviated REMARK83.  
Figure 5 illustrates the process of biomarker development and (possible) future use.  
 
1.5a. Predictive biomarkers 
Few predictive biomarkers in cancer medicine have been shown robust and have, 
as per today, been incorporated into clinical algorithms. Examples include KRAS 
mutational status in colorectal cancer indicating response to cetuximab and 
panitumumab84-86 and HER2/Neu amplification or overexpression in breast cancer 
for eligibility for trastuzumab treatment84,85,87. In endometrial cancer unfortunately 
no predictive biomarkers are available in the clinic yet to guide 
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Figure 5. Overview of biomarker development and application in personalised 
medicine.88  
The top section shows the biological levels at which biomarkers can be identified with 
the appropriate technologies. The middle section illustrates the data mining, integration 
and knowledge building processes. The third box represents the applications of 
biomarkers in personalised medicine: the right medicine at the right dose for the right 
patient. Figure adapted; reproduced with permission. 
͵ͺ
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treatment decisions. Although ERA may be considered a predictive biomarker for 
response to hormonal therapy89,90 and PIK3CA mutations are promising in 
predicting response to PI3K/mTOR inhibition (but not validated in all 
studies46,91,92); they are not used outside clinical trials so far. 
Predictive biomarkers do not have to be limited to targeted therapies, but can also 
be useful in chemotherapeutic regimens, as response rates even in chemosensitive 
diseases often do not pass 25-30%93,94. In line with this, in this thesis we have 
investigated whether stathmin1 level can be used as a predictive marker for 
response to paclitaxel based chemotherapy (this thesis). 
 
1.5b. Prognostic biomarkers 
Clinicopathological  
The strongest prognostic biomarkers in endometrial cancer are FIGO stage, 
histological subtype and tumour grade. FIGO stage is associated with increasingly 
worse survival for the higher stages2,3,72,73,95; while the overall 5-year survival rate 
in endometrial carcinoma is 78-82%2,3, it drops from 93-97% in stage 1 to 17-42% 
in stage 4 disease2,3. Other histopathological factors, indicative of increased risk of 
recurrence or lymph node metastasis, are deep myometrial invasion96,97, 
lymphovascular space invasion98,99 and tumour type and grade96,97. Tumour 
subtype is an important prognostic biomarker, with poorer 5-year survival in all 
FIGO stages for any non-endometrioid tumour subtype compared to the 
endometrioid subtype28,100. 
Molecular  
Molecular biomarkers that have shown independent prognostic value in 
endometrial cancer, focusing on survival and/or risk of lymph node metastases 
include TP53 mutation, loss of TP16, aneuploidy, loss of hormone receptors, high 
HER2 level, stathmin1 level, ȕ-catenin mutation16,55,101-103 (see also Table 1). 
(Novel) imaging methods70,104-107, serum biomarkers70,108 and tumour biomarkers 
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in preoperative specimens109-112 are all studied to assess the risk of lymph node 
metastasis, deep myometrial infiltration or cervical involvement preoperatively, 
for their utility in selecting those patients in which the benefits of the procedure 
outweigh the potential additional morbidity associated with for example complete 
pelvic and aortic lymphadenectomy113-115.  
Disease progression 
Serum markers such as Ca125 or HE4 have been studied to monitor disease 
progression, but unlike in ovarian cancer where Ca125 is strongly incorporated in 
the clinical algorithms, for various reasons there is no widespread inclusion for the 
evaluation of endometrial cancer108,116,117 
 
1.5c. Cutoff and heterogeneity 
The biomarker cutoff levels applied in different studies vary and as a result 
comparisons across literature can be difficult. Challenging the comparison of 
(potential) immunohistochemical biomarkers, is that different antibodies, targeting 
different epitopes in the same protein, could potentially give different results. 
Further, biomarkers (or biomarker signatures) are identified against a control 
population. Depending on whether the control population consists of healthy 
controls or endometrial cancers with a different subtype or different stage, the 
signature may change.  
 
1.6. Treatment 
1.6a. Surgical approach 
The main treatment algorithm for endometrial carcinoma is surgical, curative for 
most patients with early stage disease100. It consists of a total hysterectomy with 
bilateral salpingo-oophorectomy. A ‘radical’ hysterectomy (removal of uterus, 
cervix, upper vagina, parametria and pelvic lymph nodes) is performed in case of 
(suspected) cervical infiltration. The omentum is routinely removed in clear cell 
and serous tumours. Historically, the procedure was performed by laparotomy, 
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which continues to be a perfectly safe procedure, but in an increasingly obese 
population with existing comorbidities, laparoscopic procedures may show 
advantageous. Three trials explored the (dis)advantages of laparoscopy, performed 
by experienced surgeons, on clinical and/or economical outcome variables118-120, 
and in spite of considerable variation in inclusion criteria and procedural 
differences, 2 out of the 3 trials concluded that major surgery-related 
complications, including deep venous thrombosis and pulmonary embolism, 
bleeding necessitating surgery, blood transfusions, wound infections and burst 
abdomen, were reduced in the laparoscopic group but equal to laparotomy in the 
last118. But also this latter trial reported benefits in reduced hospital admission 
duration and earlier resumption of daily activities118. A cost-effectiveness analysis 
returned positive for the laparoscopic procedure121. More recently still, robotics-
assisted laparoscopy (‘robotic surgery’) has been introduced and applied to 
endometrial carcinoma surgery, with the advantages of a reduced learning curve, 
3D-vision and more natural ergonomics and hand movements for the surgeon. 
Although no trials have been published yet, two large American series, 
retrospectively comparing robotics-assisted procedures with open abdominal 
procedures in obese populations122,123, published favourable complication 
frequencies in the robotics-assisted group and equal ability to perform 
lymphadenectomy in both groups. Only one study so far compared all three 
procedures124ǡ and concluded that compared to open and routine laparoscopic 
surgery, robotics-assisted surgery was associated with low blood loss and 
complication rates, high lymph node yield and that operative time was reduced 
compared to laparoscopy. What these studies did not address is long term follow-
up or an economical comparison between robotics-assisted and normal 
laparoscopy. One level III evidence study modeled the costs associated with the 
three different types of surgery, and calculated laparoscopy to be the cheapest 
option from a hospital perspective125, strongly related to a reduced duration of 
hospital admission and the high purchasing costs for a robot. However, when 
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societal variables such as lost wages were factored in, robotics-assisted surgery 
also became a very cost-attractive option. 
 
1.6b. Lymphadenectomy 
It is known from literature that 6-8% of endometrial cancers will have pelvic 
lymph node metastasis, 4-6% pelvic and paraaortic and 2% paraaortic only70 (and 
references therein). One study reported that in patients preoperatively considered 
grade 1, stage 1 endometrioid cancer, 4.6% of patients had positive paraaortic 
lymph nodes114. Lymphadenectomy is part of a complete staging procedure and 
thus useful for risk stratification of patients. However, no survival benefit has been 
associated with the procedure in randomised clinical trials126,127. Morbidity, related 
to the procedure, includes lymphoedema (2.5-10%), thrombosis (2.6%), small 
bowel obstruction (2.3-4.4%) and lymphocysts (2.4-7.6%)114,115,128, additional to 
prolonged anaesthesia, prolonged hospital stay and increased blood loss127.  
In the US, complete paraaortic and pelvic lymphadenectomy is advised for all 
patients with endometrial carcinoma129; in Europe, this is often limited to high-risk 
categories, excluding stage 1 endometrioid tumours grade 1 and 2129-131. 
The discussion regarding lymphadenectomy in endometrial cancer suffers from 
absence of standardisation (sampling vs. complete lymphadenectomy, pelvic vs. 
pelvic and paraaortic, number of nodes needed to be removed, optimal candidate 
groups vs. all). Both trials that looked into the prognostic effects of 
lymphadenectomy in endometrial cancer126,127 have later been criticised for their 
methodology and are as such unable to give a definite answer. To oppose the trend 
of more aggressive surgery in all patients with its related risks and unclear 
prognostic benefit, different research groups aim to improve the preoperative 
identification of patients most likely to have lymph node metastases. A sentinel 
node procedure may be an alternative to balance morbidity and benefits in patients 
with a low risk of lymph node metastasis132,133. 
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Table 4. Stratification for risk of recurrence and need for adjuvant 
treatment96,97,134 
Stage Low risk  High-intermediate risk * High risk 
FIGO 1 
endometrioid 
low/medium grade 
endometrioid high grade & superficial 
invasion OR non-endometrioid 
age <60 (70) endometrioid low/medium grade  endometrioid high grade 
  & deep myometrial invasion   
  age >60 (70)   
 lymphovascular space invasion 
* 2 risk factors needed to be high-intermediate risk. In literature slight 
variability in the  risk factors describerd for this category 
. 
1.6c. Non-surgical routine treatments  
Radio- and chemotherapy 
Patients with deep myometrial invasion, higher age (>60 years), grade 3 disease or 
lymphovascular space invasion are at increased risk for recurrence of disease96,97 
(see Table 4). Therefore, in these circumstances, adjuvant treatment is. 
Radiotherapy can be offered to reduce the incidence of locoregional recurrence 
from around 20 to 5%96,97,134. However, it does not convey a survival benefit96,97,135. 
Brachytherapy has now, in one randomised trial, been shown to perform equal to 
external radiotherapy in terms of locoregional control, in intermediate to high risk  
patients reducing locoregional recurrence similarly from 20 to 5%75,135. 
Brachytherapy is associated with a significant reduction in the long term usually 
gastro-intestinal side effects (54% of patients with externam beam radiation, 
including chronic diarrhea and bowel stenosis, vs. 13% with brachytherapy)96,136. 
For high risk cases though, including most cases with non-endometrioid histology 
and higher stage tumours, external beam radiation therapy is still advised to 
guarantee optimal pelvic control137,138. In single agent chemotherapy, paclitaxel is 
the most effective with response rates of 36%, combination therapies can reach 
higher objective response rates, up to 57% (paclitaxel, cisplatin and doxorubicin) 
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against a worse side effect profile46,139. Currently, the most common regimen for 
chemotherapy in both the adjuvant and recurrent setting in endometrial cancer 
include platinum derivatives combined with taxanes. Cardiac and gastrointestinal 
side effects as well as leucopenia are common. 
Sequential combinations of radio- and chemotherapy (using different platinum 
based regimens) were compared to single radiotherapy, in early and late stage 
endometrial carcinomas94,140, with only one study94 showing significant and 
clinical relevant positive effects on progression-free survival and disease specific 
survival when combining the two strategies. Single chemotherapy treatment has 
also been compared with single radiotherapy141-143 and showed in one trial a 
significant better effect compared to external beam radiation therapy142, but also a 
clearly inferior side effect profile. The trial has been criticised methodologically, 
allowing patients with substantial residual disease after surgery (<2cm) to be 
included. Other trials have not shown superiority of chemotherapy over 
radiotherapy on clinical outcome parameters141,143. Trials are currently looking into 
the added benefit of chemo- in addition to radiotherapy, such as for example144. 
Hormonal treatment 
A large meta-analysis145 did not find evidence for clinical benefit of hormonal 
therapy in advanced endometrial cancer patients although one of the included 
studies showed a strong association between higher hormone receptor levels and 
better patient outcomes145. Some authors have reported up to 25% response rate in 
steroid receptor positive tumours46,139. Contrasting breast cancer though, where 
hormone receptor status has been incorporated in the clinical decision algorithms, 
in endometrial cancer it has not been rigorously studied in the population where 
most benefit is expected; i.e. the hormone receptor positive population with 
recurrent or advanced disease. Another review looking into the benefit of 
hormonal treatment in the adjuvant situation was also negative146. Even in 40% of 
the relevant currently active trials (Oct 23rd, 2013) registered at clinicaltrials.gov147, 
hormone status, even in only primary tumour, is not mandatory for inclusion. 
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Practically seen, there is considerable variation in type and indications of the 
adjuvant treatments offered, clearly in line with the low level of evidence for 
clinical benefit of one approach compared to another130,131,148. 
 
1.6d. Targeted treatment15,16,46,48,91 
Advances in understanding of the molecular pathogenesis of the disease have 
allowed the development of drugs specifically targeting these aberrations 
(‘targeted treatments’); with agents targeting the PI3K pathway having advanced 
furthest in endometrial cancer. Other interesting drugs currently in development or 
clinical trials are FGFR2 and HER2 inhibitors, drugs blocking angiogenesis 
though VEGF, targeting EPHA2, or HIF1A16,46. In keeping with many other 
tumour types unfortunately, poor response rates (typically up to 10%) to targeted 
treatments have been reported. However, in most occasions agents were 
administered as monotherapy without biomarker-inclusion restriction in a 
metastatic (and heavily pretreated) population16,46,91. In addition, it is becoming 
clear that combinational treatments of e.g. targeted agents in combination with 
anti-hormonal and/or chemotherapy, are likely to increase the therapeutic 
efficacy48,149.  
Finding suitable biomarkers, predictive of response to different targeted treatments, 
will be essential in making the targeted treatments fulfill their promise16,46,91 (Fig 
5). One of the reasons clinical trials do not have any biomarker restriction is 
accurately this lack of known useful biomarkers; instead, several trials test the 
patient samples for the levels of a wide panel of potential biomarkers to 
retrospectively study them for their ability to predict treatment response. 
Identifying and testing possible predictive biomarker candidates at a pre-trial stage 
(in preclinical studies and large population-based studies) is highly needed to 
assign patients to the potentially most useful clinical trials and should be further 
exploited to accelerate the identification of predictive biomarkers. The evidence 
for example that patients with PIK3CA mutations or possibly PTEN loss or 
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(phospho)AKT may respond better to PI3K/mTOR inhibition comes from 
preclinical studies, similar to that mutations in the RAS-RAF-MAPK pathway 
may convey resistance91,150. A recent small phase I study of response to 
PI3K/AKT inhibition in various cancer types including endometrial cancer, 
confirmed a substantial increase (from 10 to 33%) in response rates in the (small) 
subset of patients with PIK3CA mutations91ǡ understriking the importance of 
predictive biomarkers to improve the clinical benefit from targeted therapies. 
Another development is the hybridisation of hormone analogues to anti-neoplastic 
agents, directing the drugs to the organ of interest through the hybridisation 
molecule, with the goal to decrease side effects and increase drug efficacy139. 
 
1.7. Recurrence 
Roughly 15-20% of all endometrial cancers recur, of which a disproportionally 
high percentage belong to the non-endometrioid tumours. Percentages of 
recurrence close to 50% for the non-endometrioid and about 10-15% for the 
endometrioid tumours are often cited16,42. Three-quarter of the recurrences are 
diagnosed in the first 3 years but may come as late as 6 years after primary 
diagnosis14. In a radiotherapy-naïve population, 2/3 of the recurrences are local 
(vagina/pelvis) with a potential for curative treatment, while 1/3 are distant 
recurrences14,75,135. When the disease is systemic, average survival is 7-12 
months15,16,93, without significant improvement over the last decennia. Treatment 
options are limited and at most poorly effective. The only subgroup with a 
relatively good prognosis consists of patients with vaginal recurrences only, who 
can be treated with curative intent, allowing for a 5-year survival of 73%14. In case 
of localised or circumscribed solitary metastases, surgery and radiotherapy can be 
offered, in all other cases only chemotherapy or potentially hormonal therapy in 
hormone receptor positive tumours, are potentially useful. Unfortunately, 
radiotherapy cannot be used in areas that received a full radiation dose previously 
and in second-line chemotherapy only paclitaxel gives more than 20% response 
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rate and comes at a cost of considerable side effects139. There are therefore high 
hopes that the addition of more targeted therapies will be able to improve the 
efficacy of endometrial cancer treatment. 
 
For this overview of endometrial carcinoma, literature was searched until 
December 2013 for English-language original and overview articles in MEDLINE, 
and pubmed as well as relevant websites in English, Dutch or Norwegian. 
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2. AIMS OF THE THESIS 
2.1. Background 
Most endometrial carcinomas are diagnosed at an early stage and many can be 
treated adequately by surgery alone16,42,46. However, identifying those cases that 
are at high risk for metastasis or recurrence has proven a major challenge. Our 
ability to do so will impact prognostic estimates for the individual patients, the 
extent of surgical procedures, the need for adjuvant treatment and the intensity of 
follow-up of endometrial cancer patients. Currently, the endometrial carcinoma 
treatment algorithm is, with few exceptions, ‘organ based’ and empirical, applying 
standard adjuvant treatments regimes for higher risk cases and recurrent disease, 
irrespective of underlying molecular aberrations. Clinical response to adjuvant 
treatment and even more so treatment for recurrent disease is low, as mentioned 
previously. The identification of robust prognostic biomarkers will allow a more 
reliable identification of high risk patients, while predictive biomarkers will 
hopefully give us the tools to apply therapies in only those patients that are most 
likely to respond and thus help fulfill the promise of personalised treatment, 
including in patients with recurrent disease. But instead, surgical treatment 
paradigms have moved towards more aggressive rather than more risk-based 
(individualised) approaches and most trials on clinicaltrials.gov currently enrolling 
patients do so without limiting entry to patients more likely to benefit.  
 
2.2. General aims 
This thesis project evolved around the search for prognostic and predictive 
biomarkers in endometrial cancer, including clinical and molecular biological 
approaches with the ultimate aim to individualise and improve treatment in 
women with endometrial carcinoma.  
 
2.3. Background and aims of the individual studies 
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2.3a. Study 1 
Specific background: Staging helps clinicians to plan and evaluate treatments in 
addition to estimate an individual patient’s prognosis67. Correct staging is 
therefore extremely important. Staging systems evolve, incorporating 
improvements suggested by (multiple) large systematic studies. The latest revision 
of the (FIGO) classification system was effectuated in 2009 and included 
important changes from the previous that dates back to 198869. 
 
The specific aim was to investigate whether the FIGO 2009 staging system 
improved prognostic stratification abilities in a large, prospectively collected and 
well-annotated endometrial cancer dataset.  
 
2.3b. Study 2 
Specific background: There is an urgent need in endometrial cancer to better 
stratify patients for their risk of recurrence, as up to 20% of patients with 
presumed low risk, localised disease will face recurrences and subsequently poor 
prognosis. In endometrial cancer, contrasting many other cancers, preoperative 
histology is easily obtained and usually of sufficient quality to study. However, 
routinely, only the final operative histological specimen is used for estimation of 
prognosis and guidance towards adjuvant treatment. Discrepancy between 
preoperative and operative histological results are frequent and estimated to reach 
15-32% in various studies79,151-153, including both discrepancies in grade and 
histological subtype.  
 
The specific aim of this study was to, rather than exploring how well preoperative 
histology predicts final operative histology, specifically question the information 
content of the concordance and discordance between preoperative and operative 
histology reports, focusing on metastatic spread and prognostic significance. 
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2.3c. Study 3 
Specific background: Genome analysis techniques such as whole exome 
sequencing, genome wide expression or methylation analyses are able to give a 
wealth of information, as shown in multiple studies57,154-157. For most studies snap-
frozen tumour tissue with high tumour-cell content is required (often arbitrarily 
>80%) to obtain samples with little stromal contamination147,158. However, so far, 
it has not been investigated whether this requirement may introduce a systematic 
selection bias for specific tumour subtypes or histological grading.  
 
The specific aim of this paper was to compare tumours above and below the 
routine 80% tumour-cell content cutoff (on haematoxylin-stained frozen sections) 
for associations with clinicopathological characteristics and survival.  
 
2.3d. Study 4 
Specific background: In endometrioid and clear cell ovarian cancer, ARID1A was 
recently identified as a potential tumour suppressor gene with frequent somatic 
truncating or missense mutations and concomitant loss of protein159,160. ARID1A is 
a key member of the switch/sucrose non-fermenting (SWI/SNF) chromatin 
remodeling complex, which mobilises nucleosomes, altering accessibility of 
promoters and ultimately resulting in facilitated or repressed transcription. 
ARID1A, supposedly, confers specificity to the regulation of gene expression in 
this process161-163.  
 
The specific aim of this paper was to study the relationship between loss of 
ARID1A and standard clinicopathological variables in endometrial carcinoma, and 
specifically in the endometrioid and clear cell subtypes as they resemble the 
ovarian cancer subtypes in which the tumour suppressor gene was discovered. 
Additionally, we analysed the distribution of ARID1A loss in consecutive stages of 
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tumour progression; atypical hyperplasias, primary tumours and metastases to get 
insight in the timing of the inactivation of the gene.  
 
2.3e. Study 5 
Specific background: STMN1 is, amongst others, a regulator of microtubule 
dynamics and essential for all cells to proceed through mitosis. In many cancers, 
stathmin1 levels are elevated164-168 and elevated stathmin1 levels have been 
associated with poor prognosis and increased risk of lymph node metastasis; 
identifying stathmin1 as a prognostic biomarker55,155,166,169-172. There is preclinical 
evidence, mainly in breast cancer, suggesting stathmin1 could additionally be a 
predictive biomarker for response to taxanes treatment173-176. REMARK reporting 
recommendations are recommended and were followed in our study to ensure 
rigourous reporting and more generalisability of results83. 
 
The specific aim of this paper was, studying both endometrial cancer cell lines and 
our prospective clinical database, to question whether stathmin1 has potential as a 
predictive biomarker for response to paclitaxel containing chemotherapeutic 
regimes in endometrial cancer. We also compared stathmin1 levels in metastatic 
and primary tumours to explore potential changes in biomarker status on tumour 
progression.  
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3. GENERAL DISCUSSION 
3.1. Materials and methodological considerations: Patients 
3.1a. Patient series 
For a schematic overview of the various patient series used in the different studies, 
see Figure 6. 
 
Figure 6. Overview of used patient series, materials investigated, (types of) biomarkers 
and platforms in this thesis. 
 
Haukeland University Hospital series 
A population based series of prospectively collected endometrial cancer cases of 
patients diagnosed with and treated for the disease has been constructed at 
Haukeland University Hospital, Bergen, Norway as previously reported25. 
Haukeland University Hospital is a tertiary referral hospital for gynaecological 
oncology, covering Hordaland county, with a population just over 505 000,  
approximately 10% of the Norwegian population177, but also serving as referral 
centre for two adjacent counties (Rogaland and Sogn og Fjordane). 
All patients consented to participation prior to inclusion. Through the prospective 
character of the series, optimal data collection is guaranteed and selection or 
collection bias prevented. Patients are all treated following routine clinical 
guidelines and studies thus performed on (prospectively collected) archival tissue. 
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Samples are extensively clinically annotated, including, but not limited to, FIGO 
stage (1988 and 2009), histological subtype, grade, BMI, primary and adjuvant 
treatment, follow-up status and localisation of and treatment for any recurrent 
disease. The follow-up period extends for at least 5 years in surviving patients. 
Due to ongoing inclusion of patients and prolonged follow-up, in the various 
studies where this database was used (studies 3, 4 and 5), the total patient number 
and follow-up length varies. Figure 6 gives an overview of the various types of 
material and platforms applied for these studies.  
 
Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC)178 series) 
This is a multi-centre (n=10), multi-national (n=3) observational cohort study, 
investigating molecular markers in preoperative biopsies, in well-annotated 
patients with endometrial cancer and up to 5 years follow-up. Haukeland 
University Hospital is the coordinating centre and all patients included in the 
Haukeland series are automatically included in the MoMaTEC series too. As this 
study continues to recruit new patients, numbers of patients vary amongst the 
different studies (studies 1 and 2) where these data were used (Fig. 6). 
 
Hyperplasia cohort 
This is a series of prospectively collected cases of consented patients, diagnosed 
with endometrial hyperplasia at Haukeland University Hospital. All underwent 
hysterectomy and bilateral salpingooophorectomy for that reason between 2001 
and 2009. Similar clinicopathological information is collected as indicated for the 
endometrial carcinoma patients. Patients with hyperplasia were not subjected to 
follow-up visits and follow-up data is therefore lacking. A total of 38 patients were 
included in this series, of which 31 were diagnosed with complex hyperplasia with 
atypia. 
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The ability to study and compare the molecular characteristics of endometrial 
cancer in different stages of development (hyperplasia with atypia, primary 
tumour and (paired) metastasis) with the clinical annotations as indicated, makes 
this biobank an immensely rich source for the study of endometrial cancer. 
 
3.1b. Biobank material 
For the endometrial cancer biobank in Haukeland University Hospital, snap-frozen 
tumour tissue is collected alongside tumour tissue for the pathology department 
(FFPE tissue, subsequently collected in TMA for the biobank), urine and blood 
samples and recently also MRI imaging in patients who all have well-annotated 
clinical information. Laboratory information and (routinely) imaging results are 
routinely and consistently available. For the MoMaTEC series, curettage material 
is collected together with blood samples with similar rigorous clinical annotation. 
This allows for the performance of a wide variety of studies. Also in recurrent 
disease, FFPE tissue and/or snap-frozen tissue are collected whenever possible and 
can be paired with the related primary tumour samples for analysis (study 4 and 5).  
 
3.1c.Treatment 
Routinely, patients were subjected to hysterectomy and bilateral salpingo-
oophorectomy upon a preoperative histological confirmation of endometrial 
cancer, unless surgery was contraindicated due to severe comorbidity. Routine 
lymph node sampling was limited to pelvic lymphadenectomy for the larger part 
of the study period, with para-aortic sampling only when suspicious nodes were 
encountered during the operation. Adjuvant treatment was offered according to 
clinical guidelines, which means that in Norway, adjuvant treatment was not 
routinely offered in stage 1 or 2A (FIGO 1988) disease, but either chemotherapy 
or radiation was administered for high risk stage 1 and 2A patients (including non-
endometrioid, grade 3 and deeply infiltrating tumours) as well as stage 2B (FIGO 
1988) in the first half of the study period. Starting 2009, these patients were 
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offered chemotherapy only after surgery. Participating Swedish and Belgian 
centres offered radiation and chemotherapy to a higher percentage of patients, also 
in earlier years of study participation.  
 
3.1d. Survival 
Survival for the Haukeland series for the various FIGO stages (including both 
1988 and 2009) is indicated in Table 5 and compared to various national 
recordings. 
 
Table 5. Five-year disease specific survival data in the Haukeland 
University Hospital series and various national registries 
National registries  
FIGO 2009 HUS series SEER2 Norway3 
  % dss % os % dss   
      
Stage I 92.2 95.3 93.4 localised 
Stage II 84.7 67.5 73.3 regional 
Stage III 51.4 
Stage IV 21.4 16.9 42.3 distant 
ŽĨŶŽƚĞ͗dŚĞ,ĂƵŬĞůĂŶĚhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂůƐĞƌŝĞƐĨŽƌŵƐƌŽƵŐŚůǇϭϬйŽĨƚŚĞƚŽƚĂůEŽƌǁĞŐŝĂŶĚĂƚĂ
HUSƐĞƌŝĞƐ͗,ĂƵŬĞůĂŶĚhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂůƐĞƌŝĞƐ
 
3.1e. Absence of healthy tissue comparator 
In some cancer types, such as kidney or breast, healthy tissue is often removed 
together with the tumour and can serve as optimal comparator to investigate 
changes caused by the cancerous process, even when considering that normal 
tissue is not entirely comparable to tumour tissue, being usually less cell dense and 
more stroma rich f.e.. However, in endometrial cancer, there is usually no normal 
(non-cancerous) tissue available for comparison, in patients, nor in healthy women, 
since the endometrium is atrophic after menopause (when the majority of cancers 
arise; median age at diagnosis is 65 years in the Haukeland University Hospital as 
well as other series). This implies that in this cancer, comparisons are often made 
between different patient categories or subtypes. This has important implications, 
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as the reference population will in part determine which differences become 
visible. An interesting alternative and relatively easily feasible in endometrial 
carcinoma, is studying drivers of carcinogenesis during disease progression from 
the precancerous through to the metastatic stage, using hyperplasias with atypia 
(the precursor lesions of endometrioid endometrial carcinoma), primary tumours 
and metastatic lesions, or primary and metastatic tumours only, something that 
was explored in this thesis (study 4 and 5).  
 
3.1f.  Absence of central review 
Central review has not been applied for those studies included in the thesis that 
used material of the multi-centre MoMaTEC study (study 1 and 2). Although there 
are many valid arguments in favour of doing so, we aimed to mirror the daily 
routine in a multicentre setting, with its associated diagnostic accuracy. The high 
quality of routine reporting in academic tumour boards of the academic hospitals 
including the far majority of the MoMaTEC samples, speaks in favour of this ‘real 
world’ approach. 
 
3.2. Methods and methodological considerations: techniques used 
3.2a. IHC 
TMA 
To generate TMA, first, the area of highest tumour aggressiveness of each tumour 
is identified on hematoxylin/eosin slides to ensure tumour representativity. Then, 
0.6mm diameter tissue cylinders (three for primary tumour; one for metastasis) are 
punched out of the corresponding original FFPE tissue block and mounted in a 
recipient FFPE block using a custom-made precision instrument (Beecher 
instruments, silver spring, MD, USA). The validity of this method has been 
demonstrated in several studies179,180. 
  
Immunohistochemistry technique 
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Five ȝm thick TMA sections were first dewaxed in xylene and dehydrated in 
graded ethanol series, followed by antigen retrieval (routinely performed by 
microwave cooking in TRS pH6 (S1699 Dako Target Retrieval Solution, 20 
minutes). Then slides were blocked for peroxidase and non–specific binding 
proteins (Dako S2023, 8 minutes). Primary antibody incubation time and diluation 
for IHC varied per antibody (stathmin1: 1h, dilution 1:50 (Cell signaling #3352), 
study 5 and ARID1A: 2h, dilution 1:100 (Biosite: AT1188a), study 4). EnVision+ 
system, HRP secondary antibody was used in both cases, followed by DAB+ 
chromogen (DAKO K4011) for detection. Finally, slides were counterstained with 
hematoxylin (Dako, S2020). In IHC, antibody specificity for the protein of interest 
is crucial, therefore positive (samples with known high protein level)181,182 and 
negative (omitting primary antibody) controls are stained in each 
immunohistochemical experiment.  
Staining evaluation 
Both the intensity of staining and the proportion of tumour cells with this intensity 
are considered using standard light microscopy and assigned a classification from 
0-3 (intensity: 0 (no staining) to 3 (intense staining) and area of tumour with this 
staining from 0-3 (0; no area stained positive, 1; <10%, 2; 10-50% and 3; >50%  
area positive). The final score is then the product of intensity and area of tumour 
staining with this intensity, and varies from 0-9. Staining can be (mostly) 
cytoplasmic, nuclear, membranous and even shift with tumour progression. As 
IHC staining evaluation is a semi-quantitative method, slides are, as a rule, scored 
by two persons, blinded for patient characteristics and outcome90,183. To quantify 
the reproducibility, kappa values are calculated for all IHC series, having the same 
two persons score a random set of samples of the series independently. 
Determination of cutoff values for loss or overexpression for the individual 
proteins is data-driven (with the data usually grouped in tertiles or quartiles), 
focusing on survival differences and individual subgroup size amongst others. 
Evaluating cases with multiple metastatic lesions, in case of different scores in the 
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various samples, the assumed most pathological score was, after testing multiple 
options, chosen to be representative and relevant. 
ARID1A staining is predominantly nuclear. We decided on, in accordance with 
the first published article on the marker in New England Journal of Medicine160, a 
nuclear staining score ‘0’ as the optimal cutoff for loss of protein (assuming non- 
tumour cells and stroma scored positive in the sample). If both tumour and normal 
tissue were negative, the sample was excluded from analysis, and technical failure 
assumed. All other scores were called ‘positive’. This cutoff was used in 
hyperplasias, primary tumours and metastases. 
Staining for stathmin1 is cytoplasmic. A cutoff value for high expression had 
previously been determined in both tumour and curettage material55. After 
evaluating our metastatic stathmin1 samples, the tumour cutoff value (cytoplasmic 
staining score 9) appeared optimal to ensure consistency in scoring, and the most 
reasonable to use in view of the earlier studies. 
 
A weakness in any study using immunohistochemistry (study 4 and 5) is that 
comparisons with existing literature can be complicated by diversity in 
methodology (including antibodies, antigen retrieval and formalin fixation time), 
obscuring cancer specific hypotheses184,185 as well possibly different application of 
cutoffs. Table 6 illustrates this diversity for studies on ARID1A. As such we 
consider it important to try and adhere to standards used by authors of what can be 
called ‘marker papers’ in that specific field and increase the likelihood that 
observed results are related to signal (cancer specific differences or similarities) 
rather than noise (methology dependent). 
ͷͺ
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3.2b. Cell lines studies 
Endometrial cancer cell lines were obtained in 2009 from various suppliers and 
STR profiling, to confirm authenticity, was performed in 2012195,196. All cell lines 
were maintained under the conditions recommended by the suppliers.  
Transfection 
Cell transfections were performed using lentivirus (Open biosystems, GIPZ 
lentiviral shRNAmir; stathmin1 knock-down cells) and transfection with non-
silencing shRNAmir in a control cell population (control knock-down cells). 
Making use of the puromycin resistance gene incorporated in the shRNAmir, 
transfected cell populations were selected treating with puromycin (1ug/ml).  
Dose response experiments 
Drug treatment assays, performed in triplicate, included 24 hour paclitaxel 
treatment (range 1-500 nM) and 24 hour paclitaxel (range 1-500 nM) /carboplatin 
(fixed 200 mM) combination treatment, after which cells were either fixed in 
formaldehyde (final concentration 2%) for microscopic evaluation of apoptosis; 
used in a proliferation assay (MTS) or processed for immunoblotting. To evaluate 
apoptosis, 150 cells were counted in three different areas in 96-well plates. 
Proliferation assays were performed with CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega), adhering to the instructions from the manufacturer. 
Plates were read in an ELISA plate reader (TECAN Magellan Sunrise) at 490nm. 
Immunoblotting 
Immunoblots were performed adhering to a standard protocol. In short, cells were 
cultured and treated in 6-well plates and harvested in lysis buffer after 24 hours 
treatment. Proteins (25ug) were separated by SDS/PAGE and transferred to a 
nitrocellulose membrane (Biorad, Norway). Stathmin1 and/or cleaved PARP were 
detected using cleaved PARP (Asp214; D64E10; #5625, Cell Signaling) and 
stathmin1 (#3352, Cell Signaling), both diluted 1:1000; ȕ-actin served as a loading 
control (anti ȕ-actin antibody (AC-15; ab6276, AbCam), diluted 1:10.000; 
overnight incubation was used for all primary antibodies. Alkaline phosphatase 
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conjugated secondary antibodies were used (Anti-rabbit IgG (Sigma Aldrich 
A3687): Anti-mouse IgG (Sigma Aldrich A3562), both diluted 1:10.000) and 
chemoluminiscence substrate (lumiphos 34150 WB, Thermo scientific) for 
detection. 
 
3.2c. RNA microarray analysis 
Tissue was collected during surgery and snap-frozen in liquid nitrogen. To ensure 
data quality, all samples were evaluated for tumour purity (haematoxylin stained 
frozen sections), and included only if purity was at least 50% (majority >80%). 
Following the manufacturer’s instructions, RNA was first extracted from snap-
frozen primary tumours (RNeasy Mini Kit, Qiagen, Hilden, Germany) and 
hybridised to Agilent Whole Human Genome Microarrays 44k (Cat. no. G4112F). 
Then, arrays were scanned and features extracted using the Agilent Microarray 
Scanner Bundle. Mean spot signals were used as intensity measure and expression 
data were normalised using median over entire array (quantile normalization). 
Raw data were imported in J-Express software (Molmine, Norway) for analysis. 
Genes differentially expressed between groups were identified by SAM analysis 
and considered significant if FDR <0.01. 
 
3.2d. Statistical techniques 
Statistical analyses were all performed using the PASW18 and PASW20 Statistics 
software package (SPSS inc. Chicago, USA). Categorical variables were evaluated 
using the Pearson Ǧ or Fisher’s exact test, where applicable. Univariate 
analyses of time from primary treatment to death due to endometrial carcinoma 
(disease specific survival) were performed by the Kaplan-Meier (product-limit) 
method, with the log-rank test to compare survival between groups. Patients who 
deceased due to other causes, or surviving at the last day of follow-up, were 
censored. The Cox proportional hazards model was used for multivariate survival 
analyses (proportionality assumption confirmed), evaluating our variables of 
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interest corrected for known important clinicopathological variables. The Mann–
Whitney U test was used to correlate protein and RNA expression data. Two-sided 
P-values of 0.05 were considered significant. 
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4. SUMMARY OF RESULTS 
4.1. Study 1 
Using clinical information from the patients included in the MoMaTEC study, we 
staged a patient series including 1268 patients twice, according to FIGO 1988 and 
FIGO 2009 criteria. The correct assignment of patients to FIGO stages benefitted 
from the high percentage of lymphadenectomy (performed in 72% of stage 1 
tumours), reducing the chance of occult stage 3 disease. We show in this large and 
well-annotated dataset that the removal of 1988 stages 1A and 2A as well as a part 
of the inclusion criteria for stage 3A, major changes effectuated in the FIGO 2009 
staging system, improved the prognostic predictions, as judged by stage-dependent 
5-year disease specific survival. Surprisingly we noted that the myometrial 
infiltration depth showed a stronger prognostic impact in those patients who did 
not undergo lymphadenectomy. In this subgroup (n=243), deep myometrial 
infiltration reduced 5-year disease specific survival 28% (p=0.001); contrasting the 
group who had had lymphadenectomy performed, where this survival difference 
was minimal and not statistically significant (mainly the cases with deep 
myometrial infiltration here showed improved survival). 
FIGO 2009 staging was demonstrated to be a stronger, independent prognostic 
variable for stage 1 tumours in a Cox proportional hazards model together with 
histological subtype and grade, with and without deep myometrial infiltration 
(FIGO 2009 HR 3.91; CI 1.35-11.36, p=0.001 vs. FIGO 1988 HR 2.3; CI 0.88-
5.99), and for the subgroup with non-endometrioid histology (FIGO 2009 8.96; CI 
2.25-35.62 vs. FIGO 1988 5.86; CI 1.87-18.33).  
 
4.2. Study 2 
Histology results from preoperative and operative specimens were investigated in 
1288 patients who had complete information for both specimens; follow-up data 
was available for 1165 out of 1288. Lymphadenectomy was performed in 74% of 
patients; in 72% of cases pelvic lymphadenectomy only. Histology results for both 
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preoperative and operative specimen were categorised as low risk (grade 1 or 2 
endometrioid histology or specific for the preoperative specimen presumed 
hyperplasia only) or high risk (grade 3 endometrioid histology or non-
endometrioid histology) and concordant or discordant between preoperative and 
operative results; ultimately leading to four risk categories: low risk/low risk 
(concordant low, n=761), low risk/high risk (discordant, n=148), high risk/low risk 
(discordant, n=50) and high risk/high risk (concordant high, n=206). In total in 
16% (n=207/1288) of cases there was discordance (grade or histological subtype) 
between preoperative and operative histology. 
Discordance between preoperative and operative histology translated in an 
intermediate 5-year survival. Both discordant categories showed similar survival 
percentages, positioned between those for the concordant low and concordant high 
risk categories, in the overall study population (75 and 80% 5-year survival vs. 94 
and 58%, p<0.001) as well as specifically in stage 1 disease (87 and 93% 5-year 
survival vs. 98 and 66%, p<0.001). The combined risk classification confirmed to 
have independent prognostic value, in a Cox proportional hazards model adjusted 
for FIGO (FIGO 1-2 vs. 3-4) and age, showing a hazard rate 2.7 and 2.9 for the 
discordant groups and 5.1 for the concordant high risk group; a better independent 
prognostic factor therefore than either preoperative (HR 2.1; CI 1.3-3.2) or 
operative histology (HR 2.4; CI 1,3-3,9) on their own. 
This pattern of improved stratification with the combined preoperative/operative 
histology classification repeated itself estimating risk of positive lymph nodes that 
were present in 7% for the concordant low risk group, 23% for the concordant 
high risk group, whilst the discordant groups had positive nodes in 14 and 20% 
(p<0.001). 
 
4.3. Study 3 
We demonstrate in this correspondence, evaluating endometrial cancer patients 
with snap-frozen tissue availability (n=273/533 total dataset) that (upfront) purity 
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criteria for high throughput studies, which are arbitrarily set to include samples 
with little stromal contamination, introduce a selection bias, favouring samples 
from patients with aggressive disease. The dataset included samples with a tumour 
cell content ranging from 5-100% (mean 75% and median 80%). High tumour cell 
content was associated with high age (p<0.01), post-menopausal state (p=0.03), 
high-grade (p=0.03), non-endometrioid histology (p=0.03) and deep myometrial 
infiltration (p=0.04) but not with FIGO (2009) stage or presence of metastatic 
lymph nodes. 
For patients with tumour cell content (>80%), 5-year survival dropped to 76%, 
from 86% in patients with tumour cell content <80% (p=0.02). Five-year disease 
specific survival for all endometrial cancer patients in the series (n=553 patients, 
including patients with no snap-frozen tissue) was 82%. 
 
4.4. Study 4 
For this study we examined all 535 patients with IHC results for ARID1A, from a 
total series of 641 patients. Concerning demographical variables, patients with and 
without ARID1A staining showed similar results, and systematic selection bias of 
our cohort was therefore unlikely. ARID1A staining is nuclear and moderate to 
intense in normal tissue182,197. Loss of ARID1A staining, highly correlated with 
mutational status as published previously160,186, was noted in none of the 
hyperplasias without atypia, 16% of the hyperplasias with atypia (endometrioid 
subtype precursor lesions), 19% of the primary tumours and 28% of the metastases. 
Testing of paired primary tumours and metastases showed a borderline significant 
increase in loss of protein (p=0.054). 
Endometrioid (p=0.031) or clear cell (p=0.049) histology, (younger) age (p=0.005), 
high differentiation grade (grade 1 and 2) (p=0.007), diploid tumour status 
(p=0.002), but also deep myometrial invasion (p<0.001) were significantly 
associated with loss of ARID1A in our dataset. No relation was found with patient 
outcome (disease specific survival or recurrence free survival), nor with (lymph 
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node) metastasis. Correlation of mRNA expression data and protein levels by 
immunohistochemistry results was statistically significant (p=0.01), and mRNA 
expression was related to endometrioid histology (p=0.02) and myometrial 
infiltration depth (p=0.06). Exploring the intriguing association with deep 
myometrial infiltration for a link to EMT, we examined two gene signatures 
related to EMT102,198 for their relation with ARID1A protein levels or mRNA 
expression, without finding any support for such association.  
 
4.5. Study 5 
Using two endometrial cancer cell lines, we demonstrated increased sensitivity to 
paclitaxel treatment after stathmin1 knock-down and observed PARP cleavage at a 
lower treatment dose after knock-down (compared to the stathmin1 wild-type cell 
line). 
In our patient series, identifying 18 patients only in a series of 607 clinically well-
annotated patients, who fulfilled all criteria including recurrent or residual disease 
response data according to RECIST criteria, treatment with medication of interest, 
and stathmin1 immunohistochemistry data available, we related treatment 
response to paclitaxel with stathmin1 protein level in the tumour. Response to 
paclitaxel, but not to other treatments, was markedly better in patients with normal 
stathmin1 level compared to high stathmin1 level and statistically significant 
(p=0.027) in spite of the low patient numbers. Further, in the poor prognosis 
subgroup of patients with metastatic disease, those who were treated with 
paclitaxel and had high stathmin1 level, had a significantly reduced survival 
compared to patients treated similarly but with normal stathmin1 level (p=0.03). 
Survival was unrelated to stathmin1 protein level when alternative treatments had 
been administered (p=0.76). Also, in a multivariate model, corrected for FIGO 
stage and histological subtype, stathmin1 remained an independent predictor of 
survival, in the subgroup of patients treated with paclitaxel only (HR 2.3, CI 1.1-
5.2). 
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Finally we observed frequent discordance (26%) in stathmin1 level between paired 
primary and metastatic samples, but overall a significant increase in stathmin1 
during tumour progression (p<0.001). 
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5. STUDY APPROVALS AND GRANT SUPPORT  
The studies that constitute this thesis have been approved by the Norwegian Data 
Inspectorate (961478-2), the Norwegian Social Science Data Services (15501) and 
the local Institutional Review Board (REKIII nr. 052.01). The MoMaTEC study is 
registered at the Clinical Trials Website (NCT00598845)178.   
The overarching study, where the studies of this thesis fit into, has been supported 
by The Norwegian Cancer Society (The Harald Andersen’s legacy), Helse Vest 
Research Fund, Norwegian Research Council and The University of Bergen 
Meltzer Foundation.  
My thesis has been financially supported by the Norwegian Cancer Society, 
‘Kreftforeningen’, as indicated previously.  
The contribution of the funding sources was purely financial and did not allow any 
influence on scientific questions, methods applied, results or publication of the 
various studies. 
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6. DISCUSSION OF THE RESULTS 
This thesis is based on 5 publications evolving around the identification and 
validation of prognostic and predictive biomarkers in endometrial cancer using a 
variety of research approaches. Aware of the genetic similarities across diseases, 
such as between endometrial cancer and ovarian cancer57 or the origin of low 
grade endometrioid and clear cell ovarian tumours from endometriosis199, this 
included exploration of the potential of a novel ovarian cancer biomarker 
(ARID1A) in endometrial cancer. On the other end we have emphasised the wealth 
of not always optimally exploited information available in clinical data and have 
focused on the development of predictive and prognostic biomarkers using 
translational research. 
 
6.1. Clinical risk stratification in the molecular era 
The prognostically most important variables in endometrial cancer are FIGO 
stage, histological subtype and differentiation grade; no single other (clinical or 
molecular) biomarker has shown to have more independent prognostic value to 
date16. For the clinician they provide an important tool to stratify patients and to 
advise on various types of surgical and adjuvant treatment. In both study 1 and 2 
we benefit from the large size of the patient series and the quality of the clinical 
and follow-up data. The rationale for FIGO to revise the endometrial cancer 
staging system followed directly from analysis of a large database of endometrial 
cancer patients (n=42.000) reported to the organisation71. Using patient data from 
over 1200 patients, we show that FIGO 2009 improves as well as simplifies the 
prognostic stratification compared to the previous version that dates back to 1988. 
Contrasting some large US register studies72,73, we were able to restage all 
patients, increasing the internal validity of our results; as although these studies 
only struggled with a small percentage of the datasets (6%); it concerned those 
patients from stage 2A and 3A that actually had shifted stage. Downstaging these 
tumours should not affect the prognosis of the stages negatively, which we were 
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able to show. Additionally we included all subtypes, which may explain some of 
the differences with other studies, limited to endometrioid tumours only200. Our 
population-based approach is less biased by the limitations in diagnostic accuracy 
for histological subtyping and grading and the moderate reproducibility between 
pathologists, as these may lead to exclusion of difficult cases in studies requiring 
histopathologic revision and inclusion of only certain subtypes. 
In our study, the n=34, mostly endometrioid, patients that were downstaged from 
1988 stage 2A to 2009 stage 1A and 1B, showed a prognosis equivalent to the 
other cases in their new stages, understriking the correctness of downstaging this 
group. However, although many studies agree72,73, some do not201,202, but Cohn 
then showed a better overall prognosis for all stage 2 patients. Attempting to 
understand this discordance a few studies are of particular interest. McCluggage 
stressed the low inter-observer agreement amongst gynaecological pathologists in 
cases with deemed difficult cervical assessment (ț=0.49)76. Another, very recent, 
study noted poor agreement on routine cases with cervical involvement between 
routine pathologists focusing on different patterns of cervical involvement such as 
stromal or glandular, although there was a high level of agreement (83%) on 
overall cervical involvement203. In the latter series, a comparison with closely 
matched stage 1 and 2 patients, except for cervical involvement, did not show any 
survival differences, although cases likely have been handled differently clinically. 
Both studies discussed issues including the absence of an anatomical barrier 
between the lower uterus and the cervix, the lack of clear definitions by FIGO and 
difficulties in separating stromal and glandular involvement76,203. This raises 
concerns regarding the comparability of different studies in literature. 
Also the subgroup of stage 3A cancers due to positive cytology only is a small 
group (11 patients from our 1268 patient series), with a clearly improved 
prognosis compared to other patients in stage 3A (n=26). Literature mostly 
agrees204,205 on this and concerns have been raised that the positive cytology could 
be artificially introduced due to diagnostic hysteroscopy preceding the 
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hysterectomy206. Contrasting this, a recent study207 found that positive cytology 
independently predicted poor prognosis and a different relapse pattern, but did not 
restrict to patients with positive cytology as the only criterion for stage 3A 
inclusion. As such, although the results are very interesting and understrike the 
importance of continued reporting of positive cytology results, they do not change 
our approach to treating these patients, if no other high risk factors are detected. In 
spite of the large clinical database, both the 1988 stage 2A and stage 3A (based on 
cytology only) in our study are small however and inherently, one should be 
cautious for over-interpretation of results. It is difficult though to find even larger 
well-annotated clinical databases, especially databases that do not span multiple 
decades, with concomitant other challenges, such as major changes in primary and 
adjuvant treatment algorithms over time, affecting survival, and possibility of 
considerable missing data. 
 
Interestingly we noted that myometrial invasion depth independently added 
prognostic information in the subgroup of patients who had no lymphadenectomy 
performed (n=243) (HR 5.4, CI 1.55-18.60) but not in the subgroup of patients 
who had lymphadenectomy performed (n=649). Perhaps part of the explanation 
can be related to deep myometrial infiltration being a surrogate marker for lymph 
node metastasis100, and understrikes the importance of a critical appraisal of 
myometrial invasion, especially in those patients that did not undergo 
lymphadenectomy. The alternative interpretation is that the prognostic information 
derived from careful assessment of myometrial infiltration renders 
lymphadenectomy unnecessary, unless the staging procedure is found to improve 
survival in a randomised clinical trial, which it has failed to do to date126,127.  
  
As we noted relatively frequently, histology results do not match in grade or 
histological subtype between preoperative biopsy and hysterectomy. A study on 
the information content of this discordance and possible clinical importance was 
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therefore undertaken. Although simplifying the comparison by ignoring 
lymphadenectomy and myometrial infiltration depth in the risk assessment, our 
results hold in both the complete dataset and in the stage 1 subset where 
lymphadenectomy results are all negative. We show that discordance in 
histological subtype and grade identifies patients with an intermediate risk for 
survival and lymph node metastasis, irrespective of whether the tumour was 
qualified ‘high risk’ in the operative or preoperative specimen. This indicates that 
we may overtreat a subgroup of patients with high risk hysterectomy but not 
preoperative specimen results and who have a 17% improved disease-specific 
survival compared to the subgroup with concordant high risk in both specimens. 
At the same time, and more worrisome is that we identified a subgroup with 15% 
worse disease-specific survival than predicted by their low risk hysterectomy 
results, namely those who showed high risk histology in their preoperative 
specimens. Although these patients may benefit from adjuvant treatment, this is 
not addressed in current clinical routines that focus on hysterectomy specimens 
only. Similar observations were made for the risk of lymph node metastasis where 
the discordant subgroups showed intermediate risk compared to both concordant 
groups. Importantly, by Cox proportional hazards models and prediction analysis, 
our risk stratification has independent prognostic value. In our opinion, the extent 
of surgery alone is not the (sole) explanation for the different prognoses in the 
discordant groups compared to the concordant groups, underscored for example by 
the statistically significant different percentage of lymph node metastases in the 
groups that had equally extensive surgery based on high risk preoperative biopsies 
(14% vs. 23%, p<0.001). We therefore hypothesise several other explanations, 
including tumour heterogeneity encountered through repeated biopsy taking, 
tumours with mixed molecular or morphological characteristics or the less than 
optimal reproducibility of endometrial cancer pathology reports compared to the 
other gynaecological malignancies. The latter is supported by a number of articles, 
varying from central review of pathology reports74,208, confirmation of 
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preoperative diagnosis of hyperplastic disease only209 or interpretation of cervical 
involvement among gynaecological pathologists76, and the opportunity to combine 
two results may increase the accuracy. Heterogeneity has been demonstrated to be 
one of the bigger challenges in cancer; comparing primary tumours with their 
metastatic counterparts210-216 (this thesis), and equally subclonality within the 
primary tumour itself (which would be the heterogeneity picked up in this 
study)217-219, with single biopsies likely underestimating the tumour diversity. 
Multiple sampling will logically increase the likelihood of including more tumour 
subclones and thus tumour diversity.  
Several articles have also highlighted mixed tumours, where, in one tumour, 
serous components are admixed with endometrioid components and which show a 
worse prognosis35,47,220,221; as well as tumours with ambiguous (or hybrid) 
morphological and molecular characteristics)47,50,57,222,223, defined as tumours that 
fail to show prototypic features222. 
 
The design of our study only allowed for hypotheses for discussing our 
observations and a truly prospective and randomised study, potentially 
simultaneously recording a panel of markers that are useful in the differentiation 
of ambiguous tumours (such as PTEN, ER, PR and TP53, others?) would be very 
interesting to further explore the potential benefit to these patients, with treatment 
algorithms including adjuvant treatment for the higher risk cases, the discordant 
subgroup, we identified to have worse prognosis compared to the concordant low 
risk cases. 
 
Morphology based diagnoses are, as highlighted in different aspects by the above 
studies, highly important in terms of clinical outcome. Genetic signatures and 
molecular characteristics are closely linked to the morphological categories and 
can support them to improve diagnostic accuracy and treatment algorithms, or may 
even drive changes in current criteria for histological clasification222. Still it is 
͹͵

unlikely they will replace the standardly applied morphology, which remains the 
foundation of endometrial cancer diagnosis and treatment planning. 
 
6.2. Biomarkers in disease progression  
To investigate and address the change in biomarker status, or biomarker switch, 
between a primary tumour and one or all metastases210-216 or a pre-cancer stage 
and a cancer224,225, is one of the current major challenges in cancer research. 
Together with the challenge of intra-tumour heterogeneity, it is especially 
important in this era of targeted treatment, righteously starting to receive more 
attention. A biomarker switch can potentially signify that a targeted treatment is 
no longer relevant due to lack of target, such as a cancer which was ER+ in the 
primary tumour but ER- in the metastasis. Repeated assessment of a potential 
target during disease development has also become relevant through reported 
examples of presence of HER2 overexpression in metastases, but absent in the 
primary tumour. 
To better understand the drivers of carcinogenesis and disease progression or to 
develop new targets for treatment or screening, it is also vital to understand which 
aberrations are early or late or specifically associated with metastasis.  
 
ARID1A was a specifically interesting gene to investigate due to its recent 
discovery in ovarian cancer, and an absence of larger studies (in endometrial 
cancer) at the time of study. Mutations in ARID1A, likely a bona fide tumour 
suppressor gene154,159,160,226-228 occur frequently and throughout the gene, are often 
truncating and are highly associated with loss of protein160,186,189,227,229. In our 
study we were able to confirm a highly significant correlation between ARID1A 
RNA expression and protein levels, building further evidence that loss of protein 
by IHC is a valid assessment of ARID1A status. 
For both ARID1A (study 4) and stathmin1 (study 5) we noted that the biomarker 
frequency of the defined aberrant (and associated with cancer) protein levels, 
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increased upon disease progression, from primary tumour to metastasis and in the 
case of ARID1A we also had the opportunity to investigate and confirm this in 
hyperplasia with atypia, the endometrioid endometrial cancer preceding stage. 
The abscence of ARID1A protein already in hyperplasias with atypia (16%), but 
not in hyperplasia without atypia, may indicate that loss of ARID1A is important 
already in the earlier phases of carcinogenesis. Also Mao et al. noticed focal loss 
of ARID1A in hyperplasias with atypia187 and a recent study linked loss of 
ARID1A with incidence of sporadic MSI (in 75%), an important marker of early 
stage endometrioid endometrial cancer194, both supporting this hypothesis. In 
(atypical) endometriosis (precursor for clear cell and endometrioid ovarian 
carcinoma)160,188,191,192, and ductal carcinoma in situ (precursor of invasive breast 
cancer)230, a similar pattern was demonstrated, with some loss of ARID1A, but not 
as much as in primary tumours of the same series. Interestingly, our observation, 
that, although ARID1A loss can be noted in early stages of carcinogenesis, 
frequency of loss of protein further increase throughout tumour progression, has 
been confirmed in both endometrial and breast cancer187,230. Although not 
confirmed in our study, ARID1A has been suggested to interact with TP53 as a 
negative cell cycle regulator154,194,229 and additionally (not investigated in this 
thesis) to be associated with PI3K aberrations154,191,194. One study strikingly 
noticed increased PI3K activity measured by phosphorylation of AKT and p70S6 
in samples with loss of ARID1A and no PI3K pathway member aberrations154. 
Although literature on ARID1A is growing rapidly, few articles relate ARID1A loss 
to clinical variables including survival. However in those that do, including, but 
not limited to endometrial cancer186,188,227,230,231, all but one227 agree there is no 
significant relation with survival. This may be consistent with the importance of 
ARID1A in early stages of carcinogenesis. In endometrial cancer literature, 
agreement does exist on the association with the endometrioid187-189 and clear 
cell184,231 subtypes, being most associated with ARID1A loss, however so far there 
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is less consistency on the associations with less aggressive disease, such as lower 
grade and younger age, which are confirmed by some189, but not all187,188.  
There is a growing body of evidence that not only ARID1A, but chromatin 
remodeling complex members in general, play an important role in the 
development of many cancers232-236, although many important aspects, both 
concerning mechanistic molecular understanding and clinical relevance still need 
to be further studied. 
 
As mentioned previously, stathmin1 has been shown to be a prognostic marker in 
endometrial cancer and related to aggressive disease155,166,169-172. 
In study 5, alongside our main focus concerning a potential role for stathmin1 as a 
predictive marker in endometrial cancer, we investigated the switch, if any, in 
biomarker status between primary tumour and metastasis. There was a 
significantly higher percentage of samples with high stathmin1 level in metastases 
compared to primary tumours (18% in primary tumours vs. 37% in metastases, 
p<0.001). 
Importantly, in paired samples, discordance between primary and metastatic 
sample was 26%; in 16% there was a switch from normal to high, in 10% from 
high to normal stathmin1 level. An important consequence of this observation is 
that biomarker status as determined in the primary tumour cannot automatically be 
assumed to be similar in a metastasis. This has not only implications for novel 
targeted treatments, but also for (anti)hormonal treatment that entered the clinic a 
long time ago. Comparing ARID1A loss in primary tumour and metastatic lesions 
(unpublished data), in 17% (12/71) there was a change in biomarker status, of 
which 1% (1/71) from loss to presence of ARID1A and in the remainder 15% 
(n=11) from presence to loss of protein. In literature, similar percentages of 
discrepancy in biomarker status have been quoted in endometrial cancer103,210,213 
and in other cancer types214-216. In breast cancer, often a cancer ‘in the lead’, the 
American Society for Clinical Oncology included in 2007 for the breast cancer 
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treatment algorithms that, if the outcome would influence treatment choices, 
repeat biopsies should be considered in metastatic disease237. Although part of the 
discrepancy may be explained by sampling in an heterogeneic tumour218,219 or 
interobserver variation, the consistency of discrepancy across different 
biomarkers, studies and platforms210-217 assumes there can be a real switch in 
biomarker status between different stages of tumour progression. 
For stathmin1, this increase in overexpression in metastases fits well with its role 
as prognostic biomarker. 
 
As such, both studies contribute to the discussion regarding biomarker status in 
cancer (progression) in general, and additionally emphasize the clinical relevance 
for repeated biopsy taking. A pooled analysis in breast cancer reported repeat 
biopsy taking may directly impact treatment in 1 in every 7 patients238. The often 
heard concerns about invasive procedures forming a burden for an already sick 
patient seem irrelevant according to a recent paper where nearly 90% of patients 
would recommend the biopsy to another patient239. The same study showed a 
technical success rate of biopsy taking of 97%239. 
For article 4, we explored associations between loss of a novel biomarker, 
ARID1A, and important clinicopathological variables in endometrial cancer. And 
although we have for example looked into EMT as an explanation for the 
interesting association with deep myometrial invasion, we have not explored this 
or other associations extensively further for mechanistical explanation or 
confirmation. Although not the focus of the article, in hindsight, this could have 
deepened our understanding of the significance of this particular biomarker in 
endometrial cancer, over the hypotheses currently posited in the discussion 
section. Similarly, in article 5, further understanding of the mechanistic 
relationship between stathmin1 and taxanes will be of importance to develop 
stathmin1 further as a potential predictive biomarker. 
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6.3. Predictive biomarkers in endometrial cancer 
To increase the frequency of patients responding to treatments in the clinic and 
fulfill the promise personalised medicine has delivered to us, the identification of 
predictive markers that can tell us which patients likely will (not) respond to 
treatment (including in the metastatic setting), is an important challenge; others 
include better recognition of driver and passenger aberrations, or the design of 
rational, effective drug combinations. Through identification of likely 
(non)responders, treatment efficacy can be increased and side effects and effective 
treatment delay prevented in those who are unlikely to respond. To date, few 
predictive markers have entered the clinic, as commented previously and include 
KRAS in colorectal cancer, ALK rearrangement in non-small cell lung cancer, and 
HER2/neu amplification and overexpresson in breast cancer84-87,240,241 and none in 
endometrial cancer16. 
The most reliable way to identify a clinically relevant predictive marker and with 
reasonable certainty distinguish predictive from prognostic aspects, is through 
controlled clinical trials.  However, considering the time and cost involvement for 
these trials as well as the impact on cancer patients who would be exposed to a 
drug with its related side effects and who would assume more benefit from trial 
than from standard therapy, a lot is at stake and ideally highly likely candidates are 
lined up through alternative methods. The exploration of large prospectively 
collected patient series with high-quality clinical annotation combined with 
preclinical data, such as performed in this thesis, is well suited to fill some of this 
gap. Limitations in this approach are related to the retrospective analysis of 
prospectively collected data, and, on occasion, more rigorous imaging 
documentation at the crucial moments (prior to and after finishing metastatic 
treatments) could have resulted in inclusion of additional patients and thus a larger 
study population compliant with RECIST criteria. 
A relation between stathmin1 level and response to paclitaxel has been 
investigated preclinically in a few other epithelial cancers, including breast cancer 
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and retinoblastoma173-176, however, without confirming these findings clinically in 
the same cancer type, deemed necessary in our opinion. In our preclinical 
experiments using endometrial cancer cell lines, we demonstrated increased 
sensitivity to paclitaxel when, independent of original stathmin1 protein level, 
stathmin1 was successfully knocked down, in line with the previously mentioned 
preclinical studies173,174,176. We show this effect to be paclitaxel specific, with no 
change in sensitivity to other frequently used chemotherapeutic drugs in the 
endometrial cancer treatment, of which we tested carboplatin.  
Potentially, we could have used additional assays to quantify apoptosis better, 
such as using flowcytometry or ELISA assays. Unavailability of and/ or 
unfamiliarity with certain techniques prohibited their usage at that moment. 
We then show in our prospectively collected clinical dataset, correcting for 
important clinicopathological prognostic variables, that normal tumour stathmin1 
levels, measured by IHC, were associated with markedly and statistically 
significant improved response measured by RECIST criteria, to paclitaxel 
containing chemotherapeutical regimes compared to tumours with high stathmin1. 
We further attempted to separate out potential predictive marker characteristics 
from prognostic marker ones. In that respect, it was important to observe that, in 
patients with metastatic disease, who in general all show poor survival, those 
treated with paclitaxel and high stathmin1 tumour levels had significantly reduced 
disease specific survival compared to the patients with normal stathmin1 levels 
treated equally. This contrasted the situation in patients treated differently 
(including different chemotherapeutic regimes), where differences in disease 
specific survival were not associated with stathmin1 level, such that an association 
between high stathmin1 level and poor response to paclitaxel, where stathmin1 
level can predict the response to paclitaxel containing chemotherapeutic regimes, 
may be the underlying explanation. 
To further substantiate this biologically; platinum based agents or alkylating 
agents, of which carboplatin and also cisplatin are well known examples, exert 
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their action through cell-cycle independent DNA binding; forming cross-links and 
adducts, affecting DNA conformation and DNA repair242. Taxanes on the other 
hand, of which paclitaxel is the prototype, belong to the family of anti-microtubule 
agents that bind to microtubules thereby reducing their tendency to depolymerise 
during cell division, and as such inhibit cell cycle progression, promote mitotic 
arrest and ultimately cell death243. As a critical regulator of the dynamics of these 
same microtubules, a role for stathmin1 in the prediction of response to paclitaxel, 
but not for carboplatin is biologically conceivable. 
We feel that, in spite of the high quality of some of the purely preclinical studies, 
our study has added credibility to the assumption that stathmin1 may be(come) a 
valid predictive maker and could envisage a way forward using mouse models as a 
next and perhaps last intermediate step between our current stand and testing 
stathmin1’s predictive abilities in a clinical trial setting. 
Regarding the necessity of biomarker status retesting in metastatic lesions, very 
important in this context, I refer to the discussion in paragraph 12b.   
 
Considering that the development from bench to bedside (FDA approval for HER2 
overexpressed breast cancers244) for a pioneer targeted drug, traztuzumab, took 
approximately 25 years245, the process has already substantially improved. 
Recently, development takes approximately a third or less of this time, and 
sunitinib (SU11248), of which first publications appeared in 2003246,247, received 
FDA approval in 2006 already for advanced renal cell carcinoma and in 2011 for 
pancreatic neuroendocrine tumours248. 
 
6.4. Cross-disease focus  
An exciting and relatively new idea in cancer research to drive cancer knowledge 
is cross-disease thinking in multiple areas including cancer drivers and biomarkers 
that appear important across various cancers, or research on targeted treatment 
where knowledge in one disease can headstart studies in another (Fig. 3). TCGA is 
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taking a leader role here, through both individual disease and ‘pancancer’ 
papers57,249,250. Not only are striking similarities found, but also differences 
between cancers, giving opportunities to further understand the specific roles 
biomarkers or cancer drivers have in different tumour types. In this context the 
HER2 biomarker may serve as an example where knowledge and treatment 
opportunities learnt in breast cancer, have been applied to other cancer types with 
results at times contrasting those in breast cancer, including sometimes suboptimal 
correlation of testing across different platforms (e.g. DNA, protein)251-254. A 
potential different regulation of HER2 therefore, and/ or absence of response to 
HER2 targeted treatment in various cancer types255,256 allow for a different role or 
targetability of the protein in those diseases. And even more, juxtaposing and 
analysing tumour types with unrelated tumour types based on organ of origin, may 
potentially highlight certain cancer specificities even more. 
In the studies included in this thesis, although no cross-cancer analyses have been 
performed, some cross cancer aspects can be highlighted.  
The direct motivation for the investigation of ARID1A in endometrial cancer was 
that the two subtypes affected by loss of ARID1A both originate from 
endometriosis, and therefore have a direct link with the endometrium and per 
consequence endometrioid endometrial carcinoma (study 4). And although loss of 
ARID1A has since been linked to multiple cancer types, a large number of these 
seem specifically related to gynaecological cancers187,188,228,229,231. 
Although speculative, this suggests molecular similarity between these tumours, 
with at least one shared aberration, besides their relation through the tissue of 
origin; not shared by high grade serous ovarian or endometrial cancers.  
The selection for more aggressive tumours using a routine 80% tumour cell 
content stratification was obvious in endometrial cancer (study 3). The existence 
of a similar prognostic influence in cervical cancer subtypes has subsequently 
been investigated, and high tumour purity in the adenocarcinomas but not in the 
squamous cell carcinomas was shown, and associated with increased risk of 
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recurrent disease257. It is interesting to note that the association only holds in the 
adenocarcinomas, which may be histologically more related to endometrial 
carcinoma than squamous cell carcinomas. 
 
As a prognostic tumour marker, stathmin1 has been explored in a variety of cancer 
types, and importantly, its prognostic significance always related to more 
aggressive cases, assuming a similar effect on carcinogenesis in all. A predictive 
role of stathmin1 in different cancer types, apart from the study on endometrial 
cancer included in this thesis (study 5), has only been investigated preclinically. It 
is tempting to speculate if our clinical findings may be repeated in these cancers 
too, in line with the similarity in articles on its prognostic marker role. 
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7. CONCLUSIONS 
In a large, prospectively collected endometrial cancer dataset, the FIGO 2009 
classification system both simplified and improved prognostic stratification 
abilities compared to the previous system from 1988. (study 1) 
 
We show in a large, prospectively collected dataset that through integration of the 
preoperative histology with the final or operative histology, prognostic 
information can be further improved, especially when discordance between both 
results exists. This results in the identification of subgroups with intermediate risk 
for metastatic spread and disease specific death that currently go unnoticed. (study 
2) 
 
The 80% tumour-cell content cutoff, meant to ensure high tumour purity, is, in 
endometrial cancer, associated with high risk clinicopathological characteristics 
and reduced disease specific survival and may thus introduce an unintended 
selection bias. (study 3) 
 
In endometrial cancer, loss of ARID1A occurs most in endometrioid and clear cell 
subtypes and is, besides associated with deep myometrial infiltration, 
predominantly linked to clinicopathological parameters of less aggressive disease, 
but lacks correlation with survival. (study 4) 
 
Loss of ARID1A appears to start early in endometrioid endometrial cancer 
carcinogenesis, judged by the already existing loss in atypical hyperplasia, and 
continues to increase with tumour progression. (study 4) 
 
Integration of preclinical and clinical data supports that stathmin1 has potential as 
a predictive biomarker for response to paclitaxel containing chemotherapeutic 
regimes in endometrial cancer. (study 5) 
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Biomarker switch is a frequent phenomenon during endometrial cancrinoma 
disease progression and re-assessment of biomarker status in metastatic disease 
may be relevant. (study 4 and 5) 
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8. FUTURE PERSPECTIVES 
In the discussion section some future perspectives have already been highlighted, 
such as an emphasis on cross-disease thinking to further cancer knowledge in 
paragraph 12e. Research so far has only scraped on the surface of the potential of 
integration of knowledge across cancer types. Similar to the situation in the clinic, 
where specialists think in conceptual frameworks and diseases specific to their 
specialty, in research this is often no different and research groups and meetings 
included, are often focused on one cancer type or in the case of f.e. gynaecological 
cancers, the cancers that belong to one specialty, impeding or at least not directly 
enhancing integration of knowledge available in other diseases. As such, 
TCGA258and IGCG259 have clear potential to foment this, as well as basic and 
clinically oriented cancer meetings like AACR or ASCO where at least the 
physical distance between different topics and specialties has been minimized. 
 
Biomarkers are intrinsically related to personalised medicine, or precision 
medicine, as a newly coined term. We stand on the doorstep of a new era with 
personalised treatment in cancer, but many areas need to be further developed 
before all cancer patients will benefit from precise and personalised treatments, 
including the identification of relevant targets and associated development of 
predictive biomarkers260 (Fig. 5). Rather than finding the best treatments for the 
average patients (one size fits all; using population based study inclusion, 
routinely without molecularly characterization), as still the routine in a majority of 
cancer clinical trials91,261, the focus should be to find the best treatment for the 
individual patient, which may be quite different261. This will require a different 
approach to clinical trials, based on a firm molecular biological hypothesis, where 
biomarkers play an important role already in early clinical development. 
Incorporated already in phase 1 trials, they can assist in the identification of the 
target population and response prediction261. Phase 2 trials could then be enriched 
for patienst with the biomarker of interest, and through various alternative trial 
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designs, accrual of patients and treatment allocation could be further modified 
according to the likely  responding population261,262. A more flexible design will 
increase the chance of positive trial results, considering that in unselected patient 
populations, trials have a higher likelihood to miss positive effects due to patient 
heterogeneity, including absence of a necessary genetic aberration. 
Further, through an ongoing dialogue between the laboratory and the clinic, drug 
resistance, tumour biology and unexpected responses can be studied more timely 
and efficiently, combining patient samples and response data with preclinical 
testing91,261 .  
An approach as featured here, is expected to improve, speed up and potentially 
reduce the costs involved with the bench-to-bedside development time of new 
anti-cancer drugs, which, as also emphasised in paragraph 12d, is important for 
our patients to get speedier access to new, well tested, anti-cancer medication. 
Also part of this discussion, directly relating back to study 4 and 5, is a further 
exploration of the need to reassess biomarker status, and thus the need for repeated 
biopsy taking, in metastatic disease. It is unknown whether all biomarkers will 
show the same heterogeneity upon cancer progression, or whether for example 
certain changes are related to the type of spread, the localisation or timing of 
metastasis and prior treatment. 
 
Systems biology is a relatively new field where iterative computational modeling 
of multiple types of patient data (omics, imaging, clinical data e.g.) is combined 
with preclinical testing to drive our understanding of carcinogenesis, enhance the 
identification and development of drugs for emerging targets or to counter 
emerging drug resistance263,264. Applying systems biology approaches more 
systematically, will require team science in much larger degrees than research 
groups may be used to, with an important role for bioinformatics, alongside 
molecular biologists and doctors, and an emphasis on understanding each other’s 
language and the possibilities and limits of the various techniques. With the 
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availability of affordable large scale techniques to study DNA, RNA and recently 
also protein, as well as major advances in computational science, such a 
”marriage” has potential to drive the field further. This will allow us to perform 
network analysis rather than focusing on individual proteins or pathways, which is 
important to better understand intracellular feedback, interactions and signaling 
across different pathways, and particularly important in cancer; detect potential 
rewiring of pathways265,266. Figure 7 illustrates how systems biology approaches  
can and have linked different data sources and modeling methods to answer a 
variety of (clinical) questions. 
 Figure 7. Types of data and systems models in cancer  
The circos plot visualises different sources of data, modelling methods and questions that 
can be addressed using cancer systems approaches. The ribbons represent the multitude 
of links between data types, models and outcomes. 
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Practically, and related to this thesis, a large percentage of the samples of our 
biobank have now been run on a high throughput protein platform, RPPA267,268, 
which, through the large number of proteins quantitatively analysed, will 
hopefully allow us just that. Additionally it will give us the opportunity to 
integrate these data with RNA expression, sequencing and IHC data, the latter at 
least to date being more applicable in a routine clinical setting. To study stathmin1 
and also ARID1A using integrative analysis will further our knowledge and could 
hopefully further elucidate links between stathmin1 and also ARID1A the PI3K 
pathway154,155,194, and generate novel ones that may have  implications for future 
patient care.  
 
Preclinical models are necessary to study and test hypotheses. Models should be 
clinically relevant and replicate (part of) the biology in patients. Evidence is 
accumulating that in order to study some aspects in (endometrial) cancer; current 
models may be further optimized or combined. Endometrial cancer cell lines, as a 
model widely used in literature and used in this thesis, are sometimes poorly 
characterised clinically, and may have been passaged extensively, which can lead 
to (large) changes in genomic aberrations269. Comparing 3D with 2D (monolayer) 
cell culture, significant differences have been shown in gene expression, 
predominantly related to the extracellular matrix and related processes such as 
immune response and cell adhesion, importantly cellular responsiveness to 
chemotherapy and radiation may be also affected by growth conditions270,271 and 
as such, 3D cultures may mimic the in vivo situation better. Animal models, often 
mouse models, with subcutaneous but especially with orthotopic tumours using 
bioluminescence markers to facilitate imaging, are a further acquisition to the 
gamut, allowing monitoring tumour progression and response to interventions 
effectively272, investigation of the functional interactions between, and specific 
roles of the tumour and its (natural) microenvironment273 or for example altered 
tumourigenesis in the context of obesity. 
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As also suggested in paragraph 12d, to further the development of stathmin1 as a 
potential predictive biomarker, mouse models could be very informative, before 
possibly taking it to clinical trials. 
 
Although not a topic studied in this thesis, the still relatively disappointing results 
generated by targeted therapies, have not only led to the realisation that we need 
adequate predictive biomarkers, such as mentioned above, but also to the 
awareness that carefully studied combination therapies (whether targeted therapies 
combined with other targeted therapies, hormonal or chemotherapeutic drug) 
simulataneously blocking various pathways and possible escape (and thus 
resistance) routes for the tumour, may significantly increase response 
rates16,48,91,274. 
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9. ERRATA 
Study 1; page 104 ‘Eleven cases classified as FIGO 88 stage IIIA based on 
positive cytology only, were restaged into FIGO 09 IA (n=6), FIGO 09 IB (n=4) 
and FIGO 09 II (n=1). In this group, tumor subtype’ should read: Twelve cases 
classified as FIGO 88 stage IIIA based on positive cytology only, were restaged 
into FIGO 09 IA (n=7), FIGO 09 IB (n=4) and FIGO 09 II (n=1). In this group, 
tumor subtype was endometrioid in 67.7%. 
Study 1; page 105 table 2 footnote b ‘Five year survival 90% for patients with 
positive cytology (n=11).’ Should read ‘Five year survival 90% for patients with 
positive cytology (n=12).’ 
Study 4; page 429 ‘The hyperplasia series consists of a retrospectively collected 
series’ should read ‘The hyperplasia series consists of a prospectively collected 
series’. 
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